Freeze-dried formulations of AAV pharmaceutical products

A stable lyophilized formulation of rAAV particles with precise excipient concentrations and a lyophilization process addresses AAV stability issues, ensuring effective storage and rapid reconstitution for clinical use.

CN119072302APending Publication Date: 2024-12-03REGENERON PHARMACEUTICALS INC
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202380035210.1
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2022-03-14
Filing Date
2023-03-13
Publication Date
2024-12-03

AI Technical Summary

Technical Problem

AAV products face challenges in maintaining structural stability in aqueous environments, leading to degradation during freeze-thaw cycles and high-temperature storage, which affects viral titer and immunogenicity, and poses logistical issues for supply chain management.

Method used

A pharmaceutical formulation comprising recombinant adeno-associated virus (rAAV) particles with specific concentrations of buffer, salts, sugars, fillers, and surfactants, pH range of 6.8 to 7.8, and a lyophilization process to create stable lyophilized compositions.

Benefits of technology

The formulation maintains AAV stability and activity during storage and reconstitution, ensuring minimal degradation and efficient clinical use, with reconstitution in under 30 seconds and stability at room temperature for extended periods.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119072302A_ABST
    Figure CN119072302A_ABST
Patent Text Reader

Abstract

The present disclosure provides a stable lyophilized pharmaceutical composition comprising a recombinant adeno-associated virus (rAAV) particle. In certain embodiments, the compositions contain, in addition to the recombinant adeno-associated virus (rAAV) particles, a buffer, one or more salts, a surfactant, a filler, and a sugar. The pharmaceutical compositions of the present disclosure exhibit a considerable degree of rAAV stability upon stress and storage.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to stable lyophilized compositions of recombinant adeno-associated virus (rAAV) products, and methods for producing such compositions. Background Art

[0002] In recent years, gene therapy has attracted great interest from biopharmaceutical companies and has become a transformational strategy that can provide new treatment options for many genetic diseases. This is due to advances in virology, immunology, vector engineering technology, vector manufacturing science and other related fields, which continue to provide improved vectors that overcome safety issues associated with early gene delivery vectors (such as retroviruses). Currently, there are more than 700 gene therapy clinical trials underway or completed worldwide. Adeno-associated virus (AAV) is a non-enveloped, single-stranded DNA virus that has become an attractive therapeutic agent for delivering genetic material to host cells for gene therapy due to its ability to transduce a variety of substances and tissues in vivo, low risk of immunotoxicity, and mild innate and adaptive immune responses.

[0003] AAV gene therapy products are usually administered by injection and are formulated into liquid solutions and stored frozen at low temperatures (e.g., below -65°C). For any injection, liquid preparations are usually the preferred dosage form because they are easier to manufacture and convenient for end users. However, due to poor structural stability, maintaining the stability of AAV products in an aqueous environment can be challenging. Therefore, freezing is often used to improve the long-term storage stability of AAV by minimizing the rate of degradation due to physical and chemical instability, but freezing brings practical challenges to supply chain and inventory management. In a typical drug product (DP) manufacturing process, AAV may be exposed to a freeze-thaw process when the drug substance (DS) is frozen and stored and thawed before preparing DP filling. At least one freeze-thaw is required before the AAV DP is administered clinically. During the DP manufacturing process, subsequent packaging and labeling, and clinical application, AAV needs to be stored in a liquid state for a short period of time under ambient conditions. During freeze-thaw and high-temperature long-term storage, product degradation, such as aggregation or titer loss of AAV, may occur. Aggregation may reduce viral titer and thus product efficacy, increase the load of potentially immunogenic viral proteins, and affect biodistribution, resulting in unsustainable in vivo activity of AAV products. Therefore, maintaining the stability and activity of AAV products during manufacturing and storage is critical to the successful development of AAV as a therapeutic agent. Summary of the invention

[0004] In one aspect, the present disclosure provides a pharmaceutical formulation comprising (i) recombinant adeno-associated virus (rAAV) particles, (ii) a buffer having a concentration of about 1 mM to about 20 mM, (iii) a first salt having a concentration of about 10 mM to about 50 mM, (iv) a second salt having a concentration of about 20 mM to 100 mM, (v) a sugar having a concentration of about 1% w / v to about 10% w / v, (vi) a filler having a concentration of about 1% w / v to about 6% w / v, and (vii) a surfactant having a concentration of about 0.001% w / v to about 0.1% w / v, wherein the formulation has a pH of about 6.8 to about 7.8.

[0005] In some embodiments, the buffer is a Tris buffer or a sodium phosphate buffer. In some cases, the buffer is a Tris buffer. In some embodiments, the concentration of the buffer is 5mM to 15mM. In some cases, the concentration of the buffer is 10mM ± 2mM.

[0006] In some embodiments, the first salt is sodium chloride, potassium chloride, or magnesium chloride. In some cases, the first salt is sodium chloride. In some embodiments, the concentration of the first salt is 20 mM to 40 mM. In some cases, the concentration of the first salt is 30 mM ± 5 mM.

[0007] In some embodiments, the second salt is arginine hydrochloride. In some embodiments, the concentration of the second salt is 70mM to 90mM. In some cases, the concentration of the second salt is 80mM ± 5mM. In some embodiments, the concentration of the second salt is about 20mM to about 60mM. In some cases, the concentration of the second salt is 40mM ± 5mM. In some embodiments, the concentration of the second salt is 30mM to 90mM.

[0008] In some embodiments, the sugar is sucrose or trehalose. In some cases, the sugar is sucrose. In some embodiments, the concentration of the sugar is 3% w / v to 7% w / v. In some cases, the concentration of the sugar is 5% w / v ± 1% w / v.

[0009] In some embodiments, the filler is mannitol or glycine. In some cases, the filler is mannitol. In some embodiments, the concentration of the filler is 2% w / v to 5% w / v. In some cases, the concentration of the filler is 3.3% w / v ± 0.5% w / v.

[0010] In some embodiments, the surfactant is a polysorbate or a poloxamer. In some cases, the polysorbate is polysorbate 80 (PS80). In some cases, the poloxamer is poloxamer 188 (P188). In some embodiments, the concentration of the surfactant is 0.001% w / v to 0.1% w / v. In some cases, the surfactant concentration is 0.01% w / v ± 0.005% w / v.

[0011] In some embodiments, the pH of the formulation is 7.0 to 7.6. In some cases, the pH of the formulation is 7.3 ± 0.1.

[0012] In some embodiments, the ratio of filler to sugar is 1:1 to 1:3. In some embodiments, the ratio of filler to sugar is 1:1 to 1:7. In some cases, the ratio of mannitol to sucrose is 1:1 to 1:3. In some cases, the ratio of mannitol to sucrose is 1:1 to 1:7. In some embodiments, the ratio of mannitol to sucrose is 3.3:5. In some embodiments, the ratio of the first salt to the second salt is 1:1 to 1:4. In some cases, the ratio of sodium chloride to arginine hydrochloride is 1:1 to 1:4. In some embodiments, the ratio of sodium chloride to L-arginine hydrochloride is 3:8.

[0013] In some embodiments, the formulation has a total ionic strength of 70 mM to 120 mM. In some cases, the total ionic strength is 80 mM ± 5 mM. In some cases, the total ionic strength is 110 mM ± 10 mM.

[0014] In some embodiments, the pharmaceutical formulation has 1×10E10 vg / mL to 1×10E15 vg / mL. In some cases, the pharmaceutical formulation has 1×10E12 vg / mL to 1×10E14 vg / mL. In some cases, the pharmaceutical formulation has about 1×10E13 vg / mL.

[0015] In one aspect, the present disclosure provides a pharmaceutical formulation comprising (i) recombinant adeno-associated virus (rAAV) particles at a concentration of 1×10E10 vg / mL to 1×10E15 vg / mL, (ii) phosphate buffer at a concentration of 10 mM±1 mM, (iii) sodium chloride at a concentration of 30 mM±3 mM, (iv) L-arginine hydrochloride at a concentration of 80 mM±8 mM, (v) sucrose at a concentration of 5% w / v±0.5% w / v, (vi) mannitol at a concentration of 3.3% w / v±0.3% w / v, and (vii) poloxamer 188 at a concentration of 0.005% w / v±0.001% w / v, wherein the formulation has a pH of 7.3±0.2. In some cases, the pharmaceutical formulation has 1×10E12 vg / mL to 1×10E14 vg / mL. In some cases, the drug formulation has about 1×10E13 vg / mL.

[0016] In one aspect, the present disclosure provides a pharmaceutical formulation comprising (i) recombinant adeno-associated virus (rAAV) particles at a concentration of 1×10E10 vg / mL to 1×10E15 vg / mL, (ii) Tris buffer at a concentration of 10 mM±1 mM, (iii) sodium chloride at a concentration of 30 mM±3 mM, (iv) L-arginine hydrochloride at a concentration of 80 mM±8 mM, (v) sucrose at a concentration of 5% w / v±0.5% w / v, (vi) mannitol at a concentration of 3.3% w / v±0.3% w / v, and (vii) poloxamer 188 at a concentration of 0.01% w / v±0.002% w / v, wherein the formulation has a pH of 7.3±0.2. In some cases, the pharmaceutical formulation has 1×10E12 vg / mL to 1×10E14 vg / mL. In some cases, the drug formulation has about 1×10E13 vg / mL.

[0017] In some embodiments, the rAAV particles have serotype AAV1, AAV2, AAV3, AAV4, AAV5, AAV6, AAV7, AAV8, AAV9, AAV-DJ, AAV-DJ / 8, AAV-Rh10, AAV-retro, AAV-PHP.B, AAV8-PHP.eB, or AAV-PHP.S. In some embodiments, the rAAV particles have serotype AAV1, AAV2, AAV3, AAV4, AAV5, AAV6, AAV7, AAV8, AAV9, or AAV10. In some cases, the rAAV particles have serotype AAV1. In some cases, the rAAV particles have serotype AAV5. In some cases, the rAAV particles have serotype AAV8. In some cases, the rAAV particles have serotype AAV9.

[0018] In some embodiments, the formulation has an average particle size of about 20 nm to about 40 nm as determined by dynamic light scattering.

[0019] In some embodiments, a formulation contains a population of rAAV particles comprising at least 95% complete capsids as determined by anion exchange chromatography.

[0020] In one aspect, the present disclosure provides a stable lyophilized pharmaceutical composition formed by lyophilizing a pharmaceutical formulation discussed above or herein.

[0021] In some embodiments, the freeze-dried pharmaceutical composition has a moisture content of 1.5% or less. In some embodiments, the freeze-dried pharmaceutical composition has a moisture content of 1.0% or less. In some embodiments, the freeze-dried pharmaceutical composition has a moisture content of 0.5% to 0.8%, or 0.5%, 0.55%, 0.6%, 0.65%, 0.7%, 0.75% or 0.8%. In any of the multiple embodiments, the moisture content can be determined by Karl Fischer (Karl Fischer, KF) titration.

[0022] In some embodiments, the lyophilized pharmaceutical composition can be reconstituted in 30 seconds or less. In some embodiments, the lyophilized pharmaceutical composition can be reconstituted in 20 seconds or less. In some embodiments, the lyophilized pharmaceutical composition can be reconstituted in 15 seconds or less.

[0023] In one aspect, the present disclosure provides a reconstituted drug product formed by reconstituting a lyophilized pharmaceutical composition discussed above or herein.

[0024] In some embodiments, the reconstituted drug product has an average particle size of about 20 nm to about 40 nm as determined by dynamic light scattering.

[0025] In a certain embodiment, the reconstituted drug product comprises a group of rAAV particles comprising at least 95% complete capsids as determined by anion exchange chromatography. In some embodiments, the reconstituted drug product comprises a group of rAAV particles comprising a certain percentage of complete capsids as determined by anion exchange chromatography, wherein the percentage of complete capsids in the reconstituted drug product is within 2% of the percentage of complete capsids in the pre-lyophilized drug formulation. In some cases, the percentage of complete capsids in the reconstituted drug product is within 1% of the percentage of complete capsids in the pre-lyophilized drug formulation. In some cases, the percentage of complete capsids in the reconstituted drug product is within 0.5% of the percentage of complete capsids in the pre-lyophilized drug formulation.

[0026] In some embodiments, the reconstituted drug product has a vector genome titer as determined by droplet digital polymerase chain reaction, wherein the vector genome titer in the reconstituted drug product is within 10% of the vector genome titer present in the drug formulation prior to lyophilization. In some cases, the vector genome titer in the reconstituted drug product is within 7% of the vector genome titer present in the drug formulation prior to lyophilization.

[0027] In any of the various embodiments discussed above or herein, the reconstituted drug product may be formed by reconstituting the lyophilized drug composition after storage at a temperature of 2°C-8°C for 1 month. The reconstituted drug product, the reconstituted drug product may be formed by reconstituting the lyophilized drug composition after storage at a temperature of 2°C-8°C for 3 months. In some embodiments, the reconstituted drug product may be formed by reconstituting the lyophilized drug composition after storage at a temperature of 2°C-8°C for 6 months.

[0028] In one aspect, the present disclosure provides a container containing a pharmaceutical formulation discussed above or herein.

[0029] In one aspect, the present disclosure provides a container containing a lyophilized pharmaceutical composition discussed above or herein.

[0030] In one aspect, the present disclosure provides a container containing a reconstituted drug product discussed above or herein.

[0031] In any of the various embodiments, the container can be a glass vial.

[0032] In one aspect, the disclosure provides a kit comprising a container and instructions for use as discussed above or herein.

[0033] In one aspect, the present disclosure provides a method of producing a stable lyophilized pharmaceutical composition discussed above or herein, wherein the method comprises subjecting the pharmaceutical formulation discussed above or herein to a lyophilization process.

[0034] In some embodiments, the freeze-drying process includes (i) freezing, (ii) annealing, (iii) primary drying and (iv) secondary drying. In some cases, freezing is performed at a temperature of -45°C ± 5°C for a period of 60 minutes ± 10 minutes. In some cases, freezing is performed before and after annealing. In some cases, annealing is performed at a temperature of -20°C ± 5°C for a period of 6 hours ± 30 minutes. In some cases, primary drying is performed at a temperature of -26°C ± 5°C for a period of 50 hours ± 10 hours. In some cases, secondary drying is performed at a temperature of 35°C ± 5°C for a period of 5 hours to 20 hours. In some cases, secondary drying is performed at a temperature of 35°C ± 5°C for a period of 15 hours ± 5 hours.

[0035] In various embodiments, any features or components of the embodiments discussed above or herein can be combined, and such combinations are included in the scope of the present disclosure. Any specified value discussed above or herein can be combined with another related value discussed above or herein to list a range, and the value represents the upper and lower limits of the range, and such ranges are included in the scope of the present disclosure.

[0036] Other embodiments will become apparent upon reading the ensuing detailed description. BRIEF DESCRIPTION OF THE DRAWINGS

[0037] Figure 1A and 1B An AAV capsid containing a heterologous nucleic acid molecule (e.g., a therapeutic gene or a gene of interest (GOI)) is shown. Figure 1A ); and empty capsids, partially complete capsids, and complete capsids ( Figure 1B ).

[0038] Figure 2 Particle size distribution spectra of seven formulations evaluated in the freeze-drying feasibility study are shown (Example 2). The darker peak on the left in all figures except F7 represents the particle size before freeze-drying, while the brighter peak on the right in all figures except F7 represents the particle size after freeze-drying. The two peaks are aligned with each other in the F7 panel.

[0039] Figure 3 Particle size comparison between AAV8 and a placebo formulation (without AAV) is shown, demonstrating the presence of nanobubbles in the reconstituted composition.

[0040] Figure 4The effect of surfactant concentration in AAV formulations on AAV titer recovery is shown. As shown, 0.005% w / v of polysorbate 80 and poloxamer 188 showed comparable recovery in the test formulations, while increasing the concentration of surfactant (P188) to 0.01% w / v improved the recovery. Further increasing the surfactant concentration to 0.2% w / v did not significantly change the recovery observed at 0.01% w / v.

[0041] Figure 5 The cake structure after freeze drying for each of the two formulations in the absence of mannitol (BA1) and in the presence of mannitol (BA2) is shown. The BA2 formulation produced a cake that was more perfect in appearance and did not suffer from the production defects of the BA1 formulation.

[0042] Fig. 6A and 6B Shown are the results of thermal characterization of AAV8 formulations. Fig. 6A shows the characterization of the collapse temperature Tc observed by freeze drying microscopy, and Figure 6B The glass transition temperature Tg' observed by DSC in formulation F7 is shown.

[0043] Fig. 7A , 7B 7C show the solution form stability results of AAV8 formulations at 25° C. AAV8 vectors were formulated in F7 and stored at 25° C. for 2 days. Fig. 7A Particle size analysis by DLS is shown, Figure 7B Viral genome titer analysis by ddPCR is shown, and Figure 7C Capsid purity analysis by percentage of intact capsid using AEX-UPLC is shown.

[0044] Fig. 8A , 8B 8C and 8C show the storage stability results of the lyophilized AAV8 product in the F7 formulation at 2° C.-8° C. The results of the pre-lyophilized formulation are shown as light dots, and the results of the reconstituted lyophilized product are shown as dark dots. Fig. 8A Particle size analysis by DLS is shown, Figure 8B Viral genome titer analysis by ddPCR is shown, and Figure 8C Capsid purity analysis by percentage of intact capsid using AEX-UPLC is shown.

[0045] Fig.9A and 9B Shown are the results of salt screening for formulation preparation. Fig.9A It shows that the 13vg / mL AAV8, 10 mM tris, 30 mM NaCl, 80 mM L-Arg HCl, 5% w / v sucrose, 3.3% w / v mannitol, 0.01% w / v P188, pH 7.3 formulation (control) and formulation compositions of formulations F8 to F10 containing different types and concentrations of salts. Fig. 9B The recovery rate of post-lyophilization genome titer assessed by comparing the viral genome titer in the pre-lyophilization formulation and the reconstituted post-lyophilization product is shown.

[0046] Fig. 10A , 10B 10C and 10D show the stability results of AAV8 formulations in solution at 25°C. AAV8 vector was prepared in a solution containing 1×10 13 vg / mL AAV8, 10 mM tris, 30 mM NaCl, 80 mM L-Arg HCl, 5% w / v sucrose, 3.3% w / v mannitol, 0.01% w / v P188, pH 7.3, and then stored at 25°C for 2 days. Fig. 10A Particle size analysis by DLS is shown, Fig. 10B Viral genome titer analysis by ddPCR is shown, and Fig. 10C Capsid purity analysis by percentage of intact capsid using AEX-UPLC is shown.

[0047] Fig.11A , 11B and 11C show the formulation (1×10 13 Figure 2 shows the stability results of lyophilized AAV8 products in 1% w / v AAV8, 10 mM tris, 30 mM NaCl, 80 mM L-Arg HCl, 5% w / v sucrose, 3.3% w / v mannitol, 0.01% w / v P188, pH 7.3 at 25°C. The results of the pre-lyophilized formulation are shown as light dots, and the results of the reconstituted lyophilized product are shown as dark dots. Fig.11A Particle size analysis by DLS is shown, Fig. 11B Viral genome titer analysis by ddPCR is shown, and Fig. 11C Capsid purity analysis by percentage of intact capsid using AEX-UPLC is shown. DETAILED DESCRIPTION

[0048] Before describing the present invention, it should be understood that the present invention is not limited to the specific methods and experimental conditions described, because such methods and conditions can vary. It should also be understood that the terminology used herein is only used for the purpose of describing specific embodiments, and is not intended to be limiting, because the scope of the present invention will be limited only by the appended claims.

[0049] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which the invention belongs. As used herein, the term "about" when used in reference to a specific recited numerical value means that the value may vary by no more than 1% from the recited value. For example, as used herein, the expression "about 100" includes 99 and 101 and all values ​​therebetween (e.g., 99.1, 99.2, 99.3, 99.4, etc.).

[0050] As used herein, the terms "include, includes, and including" are intended to be non-limiting and are understood to mean "comprise, comprises, and comprising," respectively. As used herein, the term "and / or" refers to and encompasses any and all possible combinations of one or more of the associated listed items, as well as excluding combinations when interpreted in an alternative manner ("or"). As used herein, the term "or" refers to any one member of a particular list, and also includes any combination of the members of that list. As used herein, in the context of describing the present disclosure (especially in the context of the following claims), the terms "a" and "an" and "the" and similar referents should be construed to cover both the singular and the plural, unless otherwise indicated herein or clearly contradicted by context.

[0051] Although any methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present invention, the preferred methods and materials are now described. All patents, applications and non-patent publications mentioned in this specification are incorporated herein by reference in their entirety.

[0052] definition

[0053] "Adeno-associated virus" or "AAV" is a non-pathogenic parvovirus with single-stranded DNA, a genome of approximately 4.7 kb, no envelope, and an icosahedral conformation. AAV was first discovered in 1965 as a contaminant of adenovirus preparations. AAV belongs to the genus Dependovirus and the family Parvoviridae and requires the helper functions of herpesvirus or adenovirus to replicate. In the absence of a helper virus, AAV can establish latency by integrating into the 19q13.4 position of human chromosome 19. The AAV genome consists of two open reading frames (ORFs), one for each of the two AAV genes Rep and Cap. The AAV DNA ends have 145 bp inverted terminal repeats (ITRs), and the 125 terminal bases are palindromic, producing a characteristic T-shaped hairpin structure.

[0054] A "recombinant viral particle" refers to a viral particle that comprises one or more heterologous sequences (eg, nucleic acid sequences of non-viral origin), which may be flanked by at least one viral nucleotide sequence.

[0055] "Recombinant AAV particles" refer to adeno-associated virus particles comprising one or more heterologous sequences (e.g., nucleic acid sequences not derived from AAV), which may be flanked by at least one (e.g., two) AAV inverted terminal repeats (ITRs). Such rAAV particles can replicate and package when present in host cells that have been infected with a suitable helper virus (or express a suitable helper function) and express AAV rep and cap gene products (i.e., AAV Rep and Cap proteins).

[0056] "Viral particle" refers to a viral particle composed of at least one viral capsid protein and the encapsidated viral genome.

[0057] "Heterologous" means derived from an entity that is genotypically different from the rest of the entity to which it is being compared or introduced or incorporated. For example, a nucleic acid introduced into a different cell type by genetic engineering techniques is a heterologous nucleic acid (and can encode a heterologous polypeptide when expressed). Similarly, a cellular sequence (e.g., a gene or portion thereof) incorporated into a viral particle is a heterologous nucleotide sequence with respect to the viral particle.

[0058] The term "empty viral capsid" or "empty capsid" refers to a capsid that does not contain a heterologous nucleic acid molecule (e.g., a therapeutic gene), such as Figure 1B shown.

[0059] The term "partial complete viral capsid" or "partial complete capsid" refers to a capsid that contains only a portion of a heterologous nucleic acid molecule (e.g., a therapeutic gene), such as Figure 1B shown.

[0060] The term "complete viral capsid" or "complete capsid" refers to a capsid that contains all heterologous nucleic acid molecules (e.g., therapeutic genes or genes of interest), such as Figure 1B shown.

[0061] The term "pharmaceutically acceptable" used in conjunction with the compositions described herein refers to the molecular entities and other ingredients of such compositions that are physiologically tolerable and generally do not produce adverse reactions when administered to a subject. Preferably, the term "pharmaceutically acceptable" means approved by a regulatory agency of a federal or state government, or listed in the U.S. Pharmacopeia or other generally recognized pharmacopoeia for use in mammals (more specifically, humans). "Pharmaceutically acceptable salts" are salts of compounds or conjugates that can be formulated for pharmaceutical use, including, for example, metal salts (sodium salts, potassium salts, magnesium salts, calcium salts, etc.) and salts of ammonia or organic amines that are safe for administration to a subject (e.g., a human) in the form of a pharmaceutical formulation.

[0062] As used herein, "physiological concentration" of a salt refers to a concentration of a pharmaceutically acceptable salt between about 100 mM to about 200 mM.

[0063] As used herein, a "subphysiological concentration" of a salt refers to a salt concentration of a pharmaceutically acceptable salt of less than about 100 mM. In certain embodiments, a subphysiological concentration of a salt is a pharmaceutically acceptable salt of less than about 80 mM. In another embodiment, a subphysiological concentration of a salt is a pharmaceutically acceptable salt of less than about 70 mM, less than about 60 mM, less than about 50 mM, less than about 40 mM, less than about 30 mM, less than about 20 mM, or less than about 10 mM.

[0064] As used herein, the term "treat" or "treatment" of a disease condition, illness or disorder includes: (1) preventing, delaying or reducing the incidence and / or likelihood of at least one clinical or subclinical symptom of the disease condition, illness or disorder developing in a subject who may have or is susceptible to the disease condition, illness or disorder but has not yet experienced or displayed clinical or subclinical symptoms of the disease condition, illness or disorder; or (2) inhibiting the disease condition, illness or disorder, i.e., preventing, reducing or slowing the development / progression of the disease or its recurrence or at least one clinical or subclinical symptom thereof; or (3) alleviating the disease, i.e., causing the disease condition, illness or disorder or at least one clinical or subclinical symptom thereof to disappear. The use of these terms does not necessarily mean 100% or complete treatment. Instead, those of ordinary skill in the art recognize that different degrees of treatment have potential beneficial or therapeutic effects. The beneficial effects on the subjects receiving the treatment are statistically significant or at least perceptible to the patient or physician. As used herein, "therapeutically effective amount or therapeutically effective dose" or "sufficient amount or sufficient dose" refers to a dose that produces the effect of administration. The exact dosage will depend on the purpose of the treatment, and can be determined by one skilled in the art using known techniques.

[0065] The terms "patient" and "subject" are used interchangeably and in their conventional sense to refer to an organism, including humans and non-human animals, suffering from or susceptible to a condition that can be prevented or treated by administering the compositions of the present disclosure. Examples of subjects include, but are not limited to, humans, chimpanzees and other apes and monkey species; farm animals such as cattle, sheep, pigs, goats, and horses; domesticated mammals such as dogs and cats; laboratory animals, including rodents such as mice, rats, and guinea pigs; birds, including poultry, wild birds, and game birds, such as chickens, turkeys and other quail birds, ducks, geese, and the like. The term does not denote a particular age. Thus, adults, adolescents, and newborns are all contemplated.

[0066] As used herein, "storage" means that the formulation is not administered to a subject immediately after preparation, but is kept for a period of time under specific conditions (e.g., a specific temperature, etc.) before use. For example, a liquid or lyophilized formulation can be kept at different temperatures (such as refrigerated temperature (e.g., 0°C to 10°C) or room temperature (e.g., temperature up to 32°C)) for several days, weeks, months, or years before administration to a subject.

[0067] In preferred embodiments, the formulations and compositions of the present disclosure are sterile.By "sterile" is meant that the composition is substantially free of immunogenic components, such as substantially free of microorganisms (eg, fungi, bacteria, non-AAV viruses, spore forms, etc.).

[0068] General Description

[0069] The present disclosure provides preparations suitable for (e.g., after reconstitution) administration to a subject, and also suitable for long-term storage of AAV, while maintaining stability and minimizing the loss of AAV potency, e.g., pharmaceutical preparations and lyophilized compositions. In certain embodiments, the pharmaceutical preparations and compositions provided herein can maintain significant AAV activity during long-term storage. In certain embodiments, the pharmaceutical preparations and compositions discussed herein reduce or delay degradation and / or aggregation.

[0070] A particular challenge for AAV formulations and product development is that AAV products are generally not as efficient for long-term storage compared to recombinant protein-based biologics, resulting in a shorter shelf life (typically 12 to 18 months). and ) only supports a limited shelf life, i.e. 12 months at ≤-60°C, It is stable for only 14 days at 2-8°C. Freezing AAV products also presents practical challenges for supply chain and inventory management, especially when low temperatures (e.g., below -65°C) are necessary for transportation, distribution, and storage.

[0071] Freeze-dried compositions (such as the freeze-dried compositions discussed herein) address the challenges of storage and supply chain management. Specifically, the formulations and compositions of the present disclosure employ carefully selected excipients and concentrations to ensure long-term storage stability in the solid state (to support shelf life) and room temperature stability (e.g., typically at least 48 hours) in the liquid state (to support conditions for manufacturing operations and clinical / therapeutic applications). In addition, the freeze-dried compositions of the present disclosure provide freeze-dried cake perfection and acceptable reconstitution properties.

[0072] The lyophilization cycle discussed herein consists of four stages: freezing, annealing (in the presence of bulking agents such as mannitol or glycine), primary drying, and secondary drying. The drug formulation that undergoes lyophilization plays an important role in determining the quality of the drug product because the freezing and subsequent drying processes generate various stresses such as cold denaturation, solute (protein) concentration (increase due to freeze concentration), ice crystal formation, crystallization of important excipients (e.g., buffers, salts), and pH changes. If not carefully considered when selecting formulation excipients, these stresses may induce protein conformational changes and ultimately affect the stability of the lyophilized drug product.

[0073] Lyophilized AAV products face several challenges that must be addressed during formulation development. First, AAV formulations require the use of high ionic strength to prevent aggregation, but salts can greatly reduce the collapse temperature (Tc) or glass transition temperature (Tg') of amorphous systems, which may require the use of lower freezing temperatures in the freezing step, resulting in an inadequate sublimation process. Second, AAV drug products are typically formulated at low concentrations in the range of 1E12 to 1E13 vector genome copies (vg) / mL (equivalent to approximately 0.01-0.2 mg / mL), resulting in a further reduction in Tg' and the risk of losing AAV due to adsorption on different surfaces. Third, due to the low AAV concentration, fillers may need to be included in the formulation to prevent AAV from being lost from the vial during drying and to maintain the structural integrity of the lyophilized block to avoid collapse, but doing so will result in the filler being unable to fully crystallize during the annealing step and may continue to crystallize during secondary drying and subsequent storage in a dry solid form, which in turn affects the reconstitution and stability of the lyophilized drug product.

[0074] The pharmaceutical preparations and compositions disclosed herein address these and other challenges. In certain embodiments, the disclosure provides preparations of AAV, comprising a therapeutically effective amount or therapeutically effective dose of AAV, one or more buffers providing a suitable pH for the preparation, one or more pharmaceutically acceptable salts, one or more sugars and / or sugar alcohols at a stable concentration, a nonionic surfactant, and a filler. In general, the AAV preparations provided herein are suitable for drug administration.

[0075] Adeno-associated virus particles

[0076] The AAV particles can be recombinant AAV (rAAV) particles. The rAAV particles contain an AAV vector encoding a heterologous transgene or a heterologous nucleic acid molecule. The AAV particles can be avian AAV, bovine AAV, canine AAV, equine AAV, ovine AAV, primate AAV, and non-primate AAV.

[0077] In some aspects, AAV particles contain heterologous nucleic acid molecules (e.g., therapeutic genes or target genes). In some aspects, heterologous nucleic acid molecules are operably linked to promoters. Exemplary promoters include, but are not limited to, cytomegalovirus (CMV) immediate early promoter, RSV LTR, MoMLV LTR, phosphoglycerate kinase-1 (PGK) promoter, simian virus 40 (SV40) promoter and CK6 promoter, transthyretin promoter (TTR), TK promoter, tetracycline responsive promoter (TRE), HBV promoter, hAAT promoter, LSP promoter, chimeric liver-specific promoter (LSP), E2F promoter, telomerase (hTERT) promoter; cytomegalovirus enhancer / chicken β-actin / rabbit β-globin promoter and elongation factor 1-α promoter (EF1-α) promoter. In some aspects, promoters include human β-glucuronidase promoter or cytomegalovirus enhancer linked to chicken β-actin (CBA) promoter. The promoter can be a constitutive, inducible or repressible promoter. In some aspects, the present disclosure provides a recombinant vector comprising a nucleic acid encoding a heterologous transgenic disclosed herein that is operably linked to a CBA promoter. In some cases, a natural promoter or a fragment thereof of the transgenic will be used. When the expression of the transgenic needs to simulate natural expression, a natural promoter can be used. When the expression of the transgenic must be regulated in time or developmentally, or in a tissue-specific manner, or in response to a specific transcriptional stimulus, a natural promoter can be used. In another aspect, other natural expression control elements (such as enhancer elements, polyadenylation sites or Kozak consensus sequences) can also be used to simulate natural expression.

[0078] In an exemplary embodiment, the pharmaceutical preparations and compositions of the present disclosure include AAV. AAV can have any AAV serotype. In exemplary aspects, AAV has an AAV1 serotype, an AAV2 serotype, an AAV3 serotype, an AAV4 serotype, an AAV5 serotype, an AAV6 serotype, an AAV7 serotype, an AAV8 serotype, an AAV9 serotype, or an AAV10 serotype. In exemplary aspects, AAV has an AAV1 serotype. In exemplary aspects, AAV has an AAV5 serotype. In exemplary aspects, AAV has an AAV8 serotype. In exemplary aspects, AAV has an AAV9 serotype. In some cases, AAV is AAV11, AAV12, AAV-DJ, AAV-DJ / 8, AAV-Rh10, AAV-retro, AAV-PHP.B, AAV8-PHP.eB, or AAV-PHP.S. In some embodiments, the AAV particles have serotypes AAV1, AAV5, AAV8, or AAV9.

[0079] In exemplary aspects, pharmaceutical preparations and compositions include high titer AAV products. In exemplary aspects, pharmaceutical preparations and compositions include at least about 10E10 viral particles (vp) or at least about 10E11 viral particles (vp) or at least about 10E12 viral particles (vp) or at least about 10E13 viral particles (vp). In exemplary aspects, pharmaceutical preparations and compositions include at least about 10E14 viral particles (vp) or at least about 10E15 viral particles (vp), for example, at least about 2×10E15 viral particles (vp) or at least about 5×10E15 viral particles (vp). Pharmaceutical preparations and compositions also include about 10E10 vector genomes or viral genomes (vg) or at least about 10E11 vector genomes or viral genomes (vg) or at least about 10E12 vector genomes or viral genomes (vg) or at least about 10E13 vector genomes or viral genomes (vg). In exemplary aspects, the pharmaceutical preparations and compositions comprise at least about 10E14 vector genomes or viral genomes (vg) or at least about 10E15 vector genomes or viral genomes (vg), e.g., at least about 2×10E15 vector genomes or viral genomes (vg) or at least about 5×10E15 vector genomes or viral genomes (vg).

[0080] Excipients and pH

[0081] The pharmaceutical preparations and compositions of the present disclosure (including liquid pharmaceutical preparations, lyophilized pharmaceutical compositions and reconstituted pharmaceutical products, unless otherwise expressly specified) include carefully selected excipients, the concentration of which can maintain the stability of AAV particles during manufacture and use and during long-term storage under conditions that simplify supply chain logistics. In multiple embodiments, the present disclosure includes liquid pharmaceutical preparations, lyophilized pharmaceutical compositions and recombinant pharmaceutical products (e.g., as discussed above or herein) containing AAV particles and one or more buffers, one or more salts, one or more sugars or sugar alcohols, one or more fillers and one or more surfactants within a specified pH range. The concentrations discussed below or herein in conjunction with various excipients refer to liquid pharmaceutical preparations (such preparations are subsequently lyophilized), or to reconstituted compositions prepared by reconstructing lyophilized compositions. The various excipients included in the compositions of the present disclosure include salts, sugars and fillers, etc. Salts can promote the stability of AAV particles by reducing the formation of aggregates, but can also greatly reduce the collapse temperature. Sugars can act as cryoprotectants during freeze drying, but can also inhibit the crystallization of fillers. Insufficient crystallization of fillers will adversely affect the glass transition temperature and impair storage stability. Therefore, careful selection of excipients and concentrations is necessary to produce stable AAV formulations and lyophilized compositions.

[0082] A. Buffer and pH

[0083] The liquid drug preparation of the present disclosure, lyophilized pharmaceutical composition and the drug product of reconstruction include pharmaceutically acceptable buffer. In some cases, buffer includes but is not limited to phosphate buffer, histidine buffer, sodium citrate buffer, HEPES buffer, Tris buffer, Bicine buffer, glycine buffer, N-glycylglycine buffer, sodium acetate buffer, sodium carbonate buffer, glycylglycine buffer, lysine buffer, arginine buffer, sodium phosphate buffer and / or their mixture. In some embodiments, buffer is phosphate buffer (for example, sodium phosphate buffer). In some embodiments, buffer is Tris buffer.

[0084] In exemplary embodiments, the pharmaceutical compositions of the present disclosure comprise about 1 to about 30, about 1 mM to about 20 mM, about 5 mM to about 25 mM, about 5 to about 15, about 7 mM to about 13 mM, or about 8 mM to about 12 mM of a buffer. In exemplary aspects, the pharmaceutical compositions comprise about 1 mM, about 2 mM, about 3 mM, about 4 mM, about 5 mM, about 6 mM, about 7 mM, about 8 mM, about 9 mM, about 10 mM, about 11 mM, about 12 mM, about 13 mM, about 14 mM, about 15 mM, about 16 mM, about 17 mM, about 18 mM, about 19 mM, about 20 mM, about 21 mM, about 22 mM, about 23 mM, about 24 mM, or about 25 mM of a buffer.

[0085] In an exemplary embodiment, the pharmaceutical composition of the present disclosure comprises a Tris buffer of about 1mM to about 20mM, about 5mM to about 15mM, about 8mM to about 12mM, or 10mM ± 1mM. In an exemplary embodiment, the pharmaceutical composition of the present disclosure comprises a sodium phosphate buffer of about 1mM to about 20mM, about 5mM to about 15mM, about 8mM to about 12mM, or 10mM ± 1mM. In multiple embodiments, the pharmaceutical composition comprises a Tris buffer of about 5mM, about 6mM, about 7mM, about 8mM, about 9mM, about 10mM, about 11mM, about 12mM, about 13mM, about 14mM, or about 15mM. In various embodiments, the pharmaceutical composition comprises about 5mM, about 6mM, about 7mM, about 8mM, about 9mM, about 10mM, about 11mM, about 12mM, about 13mM, about 14mM, or about 15mM sodium phosphate buffer. In certain embodiments, the pharmaceutical composition comprises 10mM ± 2mM Tris buffer. In certain embodiments, the pharmaceutical composition comprises 10mM ± 2mM sodium phosphate buffer.

[0086] In exemplary embodiments, the pharmaceutical compositions of the present disclosure have a physiologically compatible pH. In certain embodiments, an AAV formulation containing a buffer suitable for maintaining the formulation at or near neutral pH is provided.

[0087] In exemplary embodiments, the pH of the pharmaceutical composition is about 6.5 to about 9.0, about 6.5 to about 8.0, about 6.9 to about 7.7, or about 7.0 to about 7.5. In certain embodiments, the pH of the formulation is about 6.5 or about 6.6, about 6.7, about 6.8, about 6.9, about 7.0, about 7.1, about 7.2, about 7.3, about 7.4, about 7.5, about 7.6, about 7.7, about 7.8, about 7.9, about 8.0, about 8.1, about 8.2, about 8.3, about 8.4, about 8.5, about 8.6, about 8.7, about 8.8, about 8.9, or about 9.0. In exemplary embodiments, the pH of the pharmaceutical composition is about 7.2, about 7.3, or about 7.4. In certain embodiments, the pH of the pharmaceutical composition is 7.3 ± 0.1. In certain embodiments, the pH of the pharmaceutical composition is 7.3 ± 0.05.

[0088] B. Salt

[0089] The liquid pharmaceutical formulations, lyophilized pharmaceutical compositions, and reconstituted drug products of the present disclosure comprise one or more pharmaceutically acceptable salts.

[0090] In various embodiments, pharmaceutically acceptable salts include, but are not limited to, metal salts such as sodium, potassium, and cesium; alkaline earth metal salts such as calcium and magnesium; organic amine salts such as triethylamine, guanidine and N-substituted guanidine, acetamidine and N-substituted acetamidine, pyridine, methylpyridine, ethanolamine, triethanolamine, dicyclohexylamine, and N,N'-dibenzylethylenediamine. Pharmaceutically acceptable salts (of basic nitrogen centers) include, but are not limited to, inorganic acid salts such as hydrochloride, hydrobromide, sulfate, phosphate; organic acid salts such as trifluoroacetate and maleate; sulfonates such as methanesulfonate, ethanesulfonate, benzenesulfonate, p-toluenesulfonate, camphorsulfonate, and naphthylsulfonate; amino acid salts such as arginine, alanine, aspartate, and glutamate; and carbohydrate salts such as gluconate and galacturonate. Non-limiting examples of pharmaceutically acceptable salts include, but are not limited to, sodium, ammonium, potassium, calcium, and magnesium salts (e.g., sodium chloride, ammonium chloride, potassium chloride, calcium chloride, and magnesium chloride; sodium acetate, ammonium acetate, potassium acetate, calcium acetate, and magnesium acetate; sodium citrate, ammonium citrate, potassium citrate, calcium citrate, and magnesium citrate; sodium phosphate, ammonium phosphate, potassium phosphate, calcium phosphate, and magnesium phosphate; sodium fluoride, ammonium fluoride, potassium fluoride, calcium fluoride, and magnesium fluoride; sodium bromide, ammonium bromide, potassium bromide, calcium bromide, and magnesium bromide; and sodium iodide, ammonium iodide, potassium iodide, calcium iodide, and magnesium iodide). In certain instances, a pharmaceutically acceptable salt is sodium chloride. In some instances, a pharmaceutically acceptable salt is arginine hydrochloride (L-arginine hydrochloride).

[0091] In an exemplary embodiment, the pharmaceutical composition of the present disclosure comprises about 0 mM to about 150 mM, about 5 mM to about 150 mM, about 5 mM to about 100 mM, about 5 mM to about 90 mM, about 5 mM to about 80 mM, about 5 mM to about 70 mM, about 5 mM to about 60 mM, about 5 mM to about 50 mM, about 5 mM to about 40 mM, 5 mM to about 30 mM, about 10 mM to about 50 mM, about 1

[0045] The invention relates to a pharmaceutically acceptable salt (as defined above; e.g., a first salt, a second salt, or a first and a second salt) of at least about 5 mM to about 45 mM, about 20 mM to about 40 mM, about 25 mM to about 35 mM, about 30 mM to about 130 mM, about 40 mM to about 120 mM, about 50 mM to about 110 mM, about 60 mM to about 100 mM, about 70 mM to about 90 mM, or about 75 mM to about 85 mM. In exemplary embodiments, the pharmaceutical composition comprises about 0 mM, about 5 mM, about 10 mM, about 15 mM, about 20 mM, about 25 mM, about 30 mM, about 35 mM, about 40 mM, about 45 mM, about 50 mM, about 55 mM, about 60 mM, about 65 mM, about 70 mM, about 75 mM, about 80 mM, about 85 mM, about 90 mM, about 95 mM, about 100 mM, about 105 mM, about 110 mM, about 115 mM, about 120 mM, about 125 mM, about 130 mM, about 135 mM, about 140 mM, about 145 mM, or about 150 mM of a pharmaceutically acceptable salt (e.g., a first salt, a second salt, or a first salt and a second salt).In some embodiments, the pharmaceutical composition comprises about 5mM, about 6mM, about 7mM, about 8mM, about 9mM, about 10mM, about 11mM, about 12mM, about 13mM, about 14mM, about 15mM, about 16mM, about 17mM, about 18mM, about 19mM, about 20mM, about 21mM, about 22mM, about 23mM, about 24mM, about 25mM, about 26mM, about 27mM, about 28mM, about 29mM, about 30mM, about 31mM, about 32mM, about 33mM, about 34mM, about 35mM, about 36mM, about 37mM, about 38mM, about 39mM, about 40mM, about 41mM, about 42mM, about 43mM, about 44mM, about 45mM, about 46mM, about 47mM, about 48mM, about 49mM, about 50mM, about 51mM, about 52mM, about 53mM, about 54mM, about 55mM, about 56mM, about 57mM, about 58mM, about 59mM, about 60mM, about 61mM, about 62mM, about 63mM, about 64mM 0mM, about 31mM, about 32mM, about 33mM, about 34mM, about 35mM, about 36mM, about 37mM, about 38mM, about 39mM, about 40mM, about 41mM, about 42mM, about 43mM, about 44mM, about 45mM, about 46mM, about 47mM, about 48mM, about 49mM, about 50mM, about 51mM, about 52mM, about 53mM, about 54mM, about 55mM, about 56mM, about 57mM mM, about 58mM, about 59mM, about 60mM, about 61mM, about 62mM, about 63mM, about 64mM, about 65mM, about 66mM, about 67mM, about 68mM, about 69mM, about 70mM, about 71mM, about 72mM, about 73mM, about 74mM, about 75mM, about 76mM, about 77mM, about 78mM, about 79mM, about 80mM, about 81mM, about 82mM, about 83mM, about 84mM In some embodiments, the present invention comprises a pharmaceutically acceptable salt (e.g., a first salt, a second salt, or a first salt and a second salt) of about 104mM, about 105mM, about 106mM, about 107mM, about 108mM, about 109mM, about 110mM, about 111mM, about 112mM, about 113mM, about 114mM, about 115mM, about 116mM, about 117mM, about 118mM, about 119mM, about 120mM, about 121mM, about 122mM, about 123mM, about 124mM, about 125mM, about 126mM, about 127mM, about 128mM, about 129mM, about 130mM, about 131mM, about 132mM, about 133mM, about 134mM, about 135mM, about 136mM, about 137mM, about 138mM, about 139mM, about 140mM, about 141mM, about 142mM, about 143mM

[0092] In certain embodiments, the pharmaceutical compositions of the present disclosure comprise about 10 mM, about 11 mM, about 12 mM, about 13 mM, about 14 mM, about 15 mM, about 16 mM, about 17 mM, about 18 mM, about 19 mM, about 20 mM, about 21 mM, about 22 mM, about 23 mM, about 24 mM, about 25 mM, about 26 mM, about 27 mM, about 28 mM, about In some embodiments, the composition comprises 30mM ± 5mM sodium chloride. In some embodiments, the composition comprises 30mM ± 3mM sodium chloride. In some embodiments, the composition comprises 30mM ± 1mM sodium chloride. In certain embodiments, the pharmaceutical compositions of the present disclosure comprise about 60 mM, about 61 mM, about 62 mM, about 63 mM, about 64 mM, about 65 mM, about 66 mM, about 67 mM, about 68 mM, about 69 mM, about 70 mM, about 71 mM, about 72 mM, about 73 mM, about 74 mM, about 75 mM, about 76 mM, about 77 mM, about 78 mM, about 79 mM. In some embodiments, the composition comprises 80mM ± 10mM arginine hydrochloride. In some embodiments, the composition comprises 80mM ± 5mM arginine hydrochloride. In some embodiments, the composition comprises 80mM ± 3mM arginine hydrochloride.

[0093] C. Surfactant

[0094] The liquid pharmaceutical formulations, lyophilized pharmaceutical compositions, and reconstituted drug products of the present disclosure comprise one or more surfactants.

[0095] As discussed herein, nonionic surfactants significantly reduce the loss of AAV on the surface and prevent the pharmaceutical composition of the present disclosure from forming visible particles. Therefore, in certain embodiments, the pharmaceutical composition contains a stable concentration of nonionic surfactants. Pharmaceutically acceptable nonionic surfactants that can be used for the compositions discussed herein include, but are not limited to, polysorbate 80 (Tween 80; PS80), polysorbate 20 (Tween 20; PS20) and various poloxamers (e.g., poloxamer 188) or mixtures thereof. In some cases, specific nonionic surfactants that may be included in the formulations and compositions of the present disclosure include, for example, polysorbates, such as polysorbate 20, polysorbate 28, polysorbate 40, polysorbate 60, polysorbate 65, polysorbate 80, polysorbate 81, and polysorbate 85; Poloxamers, such as poloxamer 181, poloxamer 188, poloxamer 407; or polyethylene glycol (PEG). In some embodiments, the nonionic surfactant used in the composition is polysorbate 80. In some embodiments, the nonionic surfactant used in the composition is poloxamer 188.

[0096] In certain embodiments, the pharmaceutical compositions of the present disclosure comprise from about 0.001% (w / v) to about 0.1% (w / v) of a nonionic surfactant. In various embodiments, the compositions comprise from about 0.001% (w / v), about 0.0015% (w / v), about 0.002% (w / v), about 0.0025% (w / v), about 0.003% (w / v), about 0.0035% (w / v), about 0.004% (w / v), about 0.0045% (w / v), about 0.005% (w / v), about 0.0 0.055% (w / v), about 0.006% (w / v), about 0.0065% (w / v), about 0.007% (w / v), about 0.0075% (w / v), about 0.008% (w / v), about 0.0085% (w / v), about 0.009% (w / v), about 0.0095% (w / v) or about 0.01% (w / v) of a non-ionic surfactant. In various embodiments, the composition comprises about 0.01% (w / v), about 0.015% (w / v), about 0.02% (w / v), about 0.025% (w / v), about 0.03% (w / v), about 0.035% (w / v), about 0.04% (w / v), about 0.045% (w / v), about 0.05% (w / v), about 0.055% (w / v), about 0.06% (w / v), about 0.065% (w / v), about 0.07% (w / v), about 0.075% (w / v), about 0.08% (w / v), about 0.085% (w / v), about 0.09% (w / v), about 0.095% (w / v), or about 0.1% (w / v) of a nonionic surfactant. In certain embodiments, the pharmaceutical compositions of the present disclosure comprise 0.005% w / v ± 0.001% w / v of a non-ionic surfactant.

[0097] In some exemplary embodiments, the pharmaceutical compositions of the present disclosure comprise about 0.001% (w / v) to about 0.01% (w / v) of polysorbate 80. In some exemplary embodiments, the pharmaceutical compositions of the present disclosure comprise about 0.001% (w / v) to about 0.01% (w / v) of poloxamer 188. In some embodiments, the pharmaceutical compositions comprise about 0.001% (w / v), about 0.0015% (w / v), about 0.002% (w / v), about 0.0025% (w / v), about 0.003% (w / v), about 0.0035% (w / v), about 0.004% (w / v), about 0.0045% (w / v), about 0.005% (w / v), about 0 .0055% (w / v), about 0.006% (w / v), about 0.0065% (w / v), about 0.007% (w / v), about 0.0075% (w / v), about 0.008% (w / v), about 0.0085% (w / v), about 0.009% (w / v), about 0.0095% (w / v) or about 0.01% (w / v) of polysorbate 80. In some embodiments, the pharmaceutical composition comprises about 0.001% (w / v), about 0.0015% (w / v), about 0.002% (w / v), about 0.0025% (w / v), about 0.003% (w / v), about 0.0035% (w / v), about 0.004% (w / v), about 0.0045% (w / v), about 0.005% (w / v), about 0 In some embodiments, the pharmaceutical compositions of the present disclosure comprise about 0.005% w / v ± 0.001% w / v of polysorbate 80. In some embodiments, the pharmaceutical compositions of the present disclosure comprise about 0.005% w / v ± 0.001% w / v of poloxamer 188.

[0098] D.Sugar

[0099] The liquid pharmaceutical formulations, lyophilized pharmaceutical compositions, and reconstituted drug products of the present disclosure comprise one or more sugars.

[0100] The addition of one of the multiple sugars (e.g., between about 1% and about 20%) improves the stability of the liquid and / or lyophilized preparation of the present disclosure. For example, sugar has better properties during the freeze / thaw cycle. Therefore, in certain embodiments, the pharmaceutical composition of the present disclosure contains about 1% to about 10% of one or more sugars. Any sugar can be used for multiple embodiments, such as monosaccharides, disaccharides or polysaccharides, or water-soluble glucans, including, for example, fructose, glucose, mannose, sorbose, xylose, maltose, lactose, sucrose, glucan, trehalose, amylopectin, dextrin, cyclodextrin, soluble starch, hydroxyethyl starch and carboxymethyl cellulose. In some embodiments, sugar is sucrose, trehalose or a combination thereof. In certain embodiments, trehalose is trehalose dihydrate. In some embodiments, sugar is sucrose. In some embodiments, sugar is trehalose.

[0101] Sugar can be used alone or in combination. In some embodiments, sugar or their combination is present in the formulation or composition at a concentration of about 1% to about 10% (w / v), about 2% (w / v) to about 8% (w / v), about 2.5% to about 7.5% (w / v), about 3% (w / v) to about 7% (w / v), or about 4% to about 6% (w / v). In some embodiments, the pharmaceutical composition of the present disclosure comprises about 1.0% (w / v), about 1.1% (w / v), about 1.2% (w / v), about 1.3% (w / v), about 1.4% (w / v), about 1.5% (w / v), about 1.6% (w / v), about 1.7% (w / v), about 1.8% (w / v), about 1.9% (w / v), about 2.0% (w / v), about 2.1% (w / v), about 2.2% (w / v), about 2.3% (w / v), about 2.4% (w / v), about 2.5% (w / v), about 2.6% (w / v), about 2.7% (w / v). , about 2.8% (w / v), about 2.9% (w / v), about 3.0% (w / v), about 3.1% (w / v), about 3.2% (w / v), about 3.3% (w / v), about 3.4% (w / v), about 3.5% (w / v), about 3.6% (w / v), about 3.7% (w / v), about 3.8% (w / v), about 3.9% (w / v), about 4.0% (w / v), about 4.1% (w / v), about 4.2% (w / v), about 4.3% (w / v), about 4.4% (w / v), about 4.5% (w / v), about 4.6% (w / v), about 4.7% (w / v). v), about 4.8% (w / v), about 4.9% (w / v), about 5.0% (w / v), about 5.1% (w / v), about 5.2% (w / v), about 5.3% (w / v), about 5.4% (w / v), about 5.5% (w / v), about 5.6% (w / v), about 5.7% (w / v), about 5.8% (w / v), about 5.9% (w / v), about 6.0% (w / v), about 6.1% (w / v), about 6.2% (w / v), about 6.3% (w / v), about 6.4% (w / v), about 6.5% (w / v), about 6.6% (w / v), about 6.7% (w / v) (w / v), about 6.8% (w / v), about 6.9% (w / v), about 7.0% (w / v), about 7.1% (w / v), about 7.2% (w / v), about 7.3% (w / v), about 7.4% (w / v), about 7.5% (w / v), about 7.6% (w / v), about 7.7% (w / v), about 7.8% (w / v), about 7.9% (w / v), about 8.0% (w / v), about 8.1% (w / v), about 8.2% (w / v), about 8.3% (w / v), about 8.4% (w / v), about 8.5% (w / v), about 8.6% (w / v), about 8.7% (w / v), about 8.8% (w / v), about 8.9% (w / v), about 9.0% (w / v), about 9.1% (w / v), about 9.2% (w / v), about 9.3% (w / v), about 9.4% (w / v), about 9.5% (w / v), about 9.6% (w / v), about 9.7% (w / v), about 9.8% (w / v), about 19.9% ​​(w / v) or about 10% (w / v) of sugars. .

[0102] In various embodiments, the compositions of the present disclosure comprise sucrose from about 2.5% w / v to about 7.5% w / v. In some embodiments, the compositions contain sucrose from 4% w / v to 6% w / v. In some embodiments, the compositions contain sucrose from 5% w / v ± 0.5% w / v. In various embodiments, the compositions of the present disclosure comprise trehalose from about 2.5% w / v to about 7.5% w / v. In some embodiments, the compositions contain trehalose from 4% w / v to 6% w / v. In some embodiments, the compositions contain trehalose from 5% w / v ± 0.5% w / v.

[0103] E. Fillers

[0104] The liquid pharmaceutical formulations, lyophilized pharmaceutical compositions, and reconstituted drug products of the present disclosure comprise one or more fillers.

[0105] The addition of one of the multiple sugars (e.g., between about 1% to about 10%) improves the stability of the liquid and / or lyophilized formulations of the present disclosure. For example, fillers as discussed herein allow production of better lyophilized compositions with improved stability and reconstitution properties. Therefore, in certain embodiments, the pharmaceutical composition of the present disclosure contains one or more fillers of about 1% to about 10%. In multiple embodiments, the filler included in the pharmaceutical composition of the present disclosure may include but is not limited to mannitol, glycine, polymers (such as dextran, polyvinyl pyrrolidone, carboxymethyl cellulose), lactose, sorbitol or xylitol. In some embodiments, the filler is mannitol. In some embodiments, the filler is glycine.

[0106] Fillers can be used alone or in combination. In some embodiments, fillers or their combinations are present in the formulation or composition at a concentration of about 1% to about 10% (w / v), about 1% (w / v) to about 6% (w / v), about 2% to about 4% (w / v), or about 3% (w / v) to about 3.5% (w / v). In some embodiments, the pharmaceutical composition of the present disclosure comprises about 1.0% (w / v), about 1.1% (w / v), about 1.2% (w / v), about 1.3% (w / v), about 1.4% (w / v), about 1.5% (w / v), about 1.6% (w / v), about 1.7% (w / v), about 1.8% (w / v), about 1.9% (w / v), about 2.0% (w / v), about 2.1% (w / v), about 2.2% (w / v), about 2.3% (w / v), about 2.4% (w / v), about 2.5% (w / v), about 2.6% (w / v), about 2.7% (w / v), about 2 .8% (w / v), about 2.9% (w / v), about 3.0% (w / v), about 3.1% (w / v), about 3.2% (w / v), about 3.3% (w / v), about 3.4% (w / v), about 3.5% (w / v), about 3.6% (w / v), about 3.7% (w / v), about 3.8% (w / v), about 3.9% (w / v), about 4.0% (w / v), about 4.1% (w / v), about 4.2% (w / v), about 4.3% (w / v), about 4.4% (w / v), about 4.5% (w / v), about 4.6% (w / v), about 4.7% (w / v), about 4 .8% (w / v), about 4.9% (w / v), about 5.0% (w / v), about 5.1% (w / v), about 5.2% (w / v), about 5.3% (w / v), about 5.4% (w / v), about 5.5% (w / v), about 5.6% (w / v), about 5.7% (w / v), about 5.8% (w / v), about 5.9% (w / v), about 6.0% (w / v), about 6.1% (w / v), about 6.2% (w / v), about 6.3% (w / v), about 6.4% (w / v), about 6.5% (w / v), about 6.6% (w / v), about 6.7% (w / v), about 6 .8% (w / v), about 6.9% (w / v), about 7.0% (w / v), about 7.1% (w / v), about 7.2% (w / v), about 7.3% (w / v), about 7.4% (w / v), about 7.5% (w / v), about 7.6% (w / v), about 7.7% (w / v), about 7.8% (w / v), about 7.9% (w / v), about 8.0% (w / v), about 8.1% (w / v), about 8.2% (w / v), about 8.3% (w / v), about 8.4% (w / v), about 8.5% (w / v), about 8.6% (w / v), about 8.7% (w / v), about 8.8% (w / v), about 8.9% (w / v), about 9.0% (w / v), about 9.1% (w / v), about 9.2% (w / v), about 9.3% (w / v), about 9.4% (w / v), about 9.5% (w / v), about 9.6% (w / v), about 9.7% (w / v), about 9.8% (w / v), about 19.9% ​​(w / v), or about 10% (w / v) of filler. .

[0107] In various embodiments, the compositions of the present disclosure comprise mannitol from about 2% w / v to about 4.5% w / v. In some embodiments, the compositions contain mannitol from 3% w / v to 3.5% w / v. In some embodiments, the compositions contain mannitol from 3.3% w / v ± 0.1% w / v. In various embodiments, the compositions of the present disclosure comprise glycine from about 2% w / v to about 4.5% w / v. In some embodiments, the compositions contain glycine from 3% w / v to 3.5% w / v. In some embodiments, the compositions contain glycine from 3.3% w / v ± 0.1% w / v.

[0108] F. Ratio of excipients

[0109] In multiple embodiments, the liquid pharmaceutical formulations, lyophilized pharmaceutical compositions, and reconstituted pharmaceutical products of the present disclosure include specific excipients at a specified ratio to enhance the stability of the composition. In some embodiments, the composition includes fillers and sugars (fillers: sugars) at a specified ratio. In some embodiments, the composition includes two salts (first salt: second salt) at a specified ratio.

[0110] In some cases, the ratio of filler: sugar is about 1: 1 to 1: 10. In various embodiments, the ratio of filler: sugar is about 1: 1, about 1: 2, about 1: 3, about 1: 4, about 1: 5, about 1: 6, about 1: 7, about 1: 8, about 1: 9, about 1: 10, about 2: 3, about 2: 5, about 2: 7, about 2: 9, about 3: 4, about 3: 5, about 3: 7, about 3: 8, about 3: 10, about 4: 5, about 4: 7, about 4: 9, about 5: 6, about 5: 7, about 5: 8, about 5: 9, about 6: 7, about 7: 8, about 7: 9, about 7: 10, or about 8: 9. In some embodiments, the ratio of filler: sugar is about 3.1: 5, about 3.2: 5, about 3.3: 5, about 3.4: 5, or about 3.5: 5. In some cases, the ratio of bulking agent:sugar is 3.3:5. In some cases, the bulking agent is mannitol,

[0111] And the sugar is sucrose, and the ratio of mannitol:sucrose is about 1:1 to 1: 10. In various embodiments, the ratio of mannitol:sucrose is about 1:1, about 1:2, about 1:3, about 1:4, about 1:5, about 1:6, about 1:7, about 1:8, about 1:9, about 1:10, about 2:3, about 2:5, about 2:7, about 2:9, about 3:4, about 3:5, about 3:7, about 3:8, about 3:10, about 4:5, about 4:7, about 4:9, about 5:6, about 5:7, about 5:8, about 5:9, about 6:7, about 7:8, about 7:9, about 7:10, or about 8:9. In some embodiments, the ratio of mannitol: sucrose is about 2.8: 5, about 2.9: 5, about 3.0: 5, about 3.1: 5, about 3.2: 5, about 3.3: 5, about 3.4: 5, about 3.5: 5, about 3.6: 5, about 3.7: 5, or about 3.8: 5. In some cases, the ratio of mannitol: sucrose is 3.3: 5.

[0112] In some cases, the ratio of the first salt: the second salt is about 1: 1 to 1: 10. In various embodiments, the ratio of the first salt: the second salt is about 1: 1, about 1: 2, about 1: 3, about 1: 4, about 1: 5, about 1: 6, about 1: 7, about 1: 8, about 1: 9, about 1: 10, about 2: 3, about 2: 5, about 2: 7, about 2: 9, about 3: 4, about 3: 5, about 3: 7, about 3: 8, about 3: 10, about 4: 5, about 4: 7, about 4: 9, about 5: 6, about 5: 7, about 5: 8, about 5: 9, about 6: 7, about 7: 8, about 7: 9, about 7: 10, or about 8: 9. In some embodiments, the ratio of the first salt: the second salt is about 2.5: 8, about 2.6: 8, about 2.7: 8, about 2.8: 8, about 2.9: 8, about 3.0: 8, about 3.1: 8, about 3.2: 8, about 3.3: 8, about 3.4: 8, or about 3.5: 8. In some cases, the ratio of the first salt: the second salt is 3: 8. In some cases, the first salt is sodium chloride and the second salt is L-arginine hydrochloride, and the ratio of sodium chloride: L-arginine hydrochloride is about 1: 1 to 1: 10. In various embodiments, the ratio of sodium chloride:L-arginine hydrochloride is about 1:1, about 1:2, about 1:3, about 1:4, about 1:5, about 1:6, about 1:7, about 1:8, about 1:9, about 1:10, about 2:3, about 2:5, about 2:7, about 2:9, about 3:4, about 3:5, about 3:7, about 3:8, about 3:10, about 4:5, about 4:7, about 4:9, about 5:6, about 5:7, about 5:8, about 5:9, about 6:7, about 7:8, about 7:9, about 7:10, or about 8:9. In some embodiments, the ratio of sodium chloride: L-arginine hydrochloride is about 2.5: 8, about 2.6: 8, about 2.7: 8, about 2.8: 8, about 2.9: 8, about 3.0: 8, about 3.1: 8, about 3.2: 8, about 3.3: 8, about 3.4: 8, or about 3.5: 8. In some cases, the ratio of sodium chloride: L-arginine hydrochloride is 3:8.

[0113] G. Additional Optional Components

[0114] The liquid pharmaceutical formulations, lyophilized pharmaceutical compositions, and reconstituted drug products of the present disclosure may also optionally comprise additional components. In exemplary embodiments, the formulation or pharmaceutical composition comprises any one or a combination of the following: an acidifier, an additive, an adsorbent, an air displacer, an alkalizing agent, an anticaking agent, an anticoagulant, an antimicrobial preservative, an antioxidant, a preservative, a base, a binder, a buffer, a chelating agent, a coating agent, a colorant, a desiccant, a detergent, a diluent, a bactericide, a disintegrant, a dissolution promoter, a dye, an emollient, an emulsifier, an emulsion stabilizer, a filler, a film former, a flavor enhancer, a flavoring agent, a flow enhancer, a gelling agent, a granulating agent, a humectant, a lubricant, a mucoadhesive, an ointment base, an ointment, an oily vehicle, an organic base, a pastille base, a pigment, a plasticizer, a polishing agent, a preservative, a sequestering agent, a solubilizing agent, a solvent, a stabilizer, a surface-active agent, a surfactant, a suspending agent, a sweetener, a therapeutic agent, a thickener, a tonicity agent, a viscosity increasing agent, a water absorbent, a water-miscible cosolvent, a water softener, or a wetting agent.

[0115] Lyophilization and composition

[0116] The lyophilized composition is prepared by lyophilizing the pharmaceutical formulations discussed above or herein. In various aspects, the present disclosure includes such lyophilized compositions, as well as methods of producing stable lyophilized pharmaceutical compositions. Embodiments of the methods of producing lyophilized AAV compositions discussed herein may also include producing an aqueous formulation followed by lyophilization.

[0117] The freeze-drying process generally includes (i) freezing, (ii) annealing, (iii) primary drying and (iv) secondary drying. In some cases, freezing is performed at a temperature of -45°C ± 5°C for a period of 60 minutes ± 10 minutes. In some cases, freezing is performed before and after annealing. In some cases, annealing is performed at a temperature of -20°C ± 5°C for a period of 6 hours ± 30 minutes. In some cases, primary drying is performed at a temperature of -26°C ± 5°C for a period of 50 hours ± 10 hours. In some cases, secondary drying is performed at a temperature of 35°C ± 5°C for a period of 5 to 20 hours or a period of 15 hours ± 5 hours.

[0118] In one embodiment, the rAAV sample is loaded into a glass vial and placed in a freeze drying chamber. The sample can be initially incubated at about 5°C for about 60 minutes, then cooled from about 5°C to about -45°C at a ramp rate of about 0.5°C / minute, and then kept at a constant temperature for about 60 minutes. Annealing can be performed at about -20°C at a ramp rate of about 0.5°C / minute for about 6 hours, then cooled back to about -45°C at a ramp rate of about 0.5°C / minute, and then kept for about 60 minutes. The primary drying can be performed at about -26°C and a room pressure of about 50 mTorr for about 50 hours, and then the secondary drying is performed at about 35°C and about 100 mTorr for about 10 hours or 15 hours, and the ramp rate for both the primary drying and the secondary drying is about 0.3°C / minute. At the end of the freeze drying cycle, the sample can be backfilled with nitrogen at about 80% atmospheric pressure, then capped and sealed.

[0119] In one embodiment, the rAAV sample is placed in a glass vial and placed in a freeze drying chamber. The sample can be initially incubated at a temperature of about 1°C to about 10°C for a period of about 30 minutes to about 90 minutes, then cooled from the incubation temperature to a freezing temperature of about -30°C to about -60°C at a ramp rate of about 0.1°C / minute to about 1°C / minute, and then kept at a constant temperature for a period of about 30 minutes to about 90 minutes. Annealing can be performed at a temperature of about -10°C to about -30°C at a ramp rate of about 0.1°C / minute to about 1°C / minute for about 4 hours to about 8 hours, and then the sample can be cooled back to a temperature of about -30°C to about -60°C at a ramp rate of about 0.1°C / minute to about 1°C / minute, and then kept for a period of about 30 minutes to about 90 minutes. The primary drying can be carried out at a temperature of about -20°C to about -30°C, at a room pressure of about 40 mTorr to about 60 mTorr for a period of about 40 hours to about 60 hours, and then the secondary drying is carried out at a temperature of about 25°C to about 45°C, at a pressure of about 75 mTorr to about 125 mTorr for a period of about 5 hours to about 20 hours, and the ramp rate of both the primary drying and the secondary drying is about 0.1°C / minute to about 1°C / minute. At the end of the freeze-drying cycle, the sample can be backfilled with nitrogen at about 70%-90% of atmospheric pressure, and then capped and sealed.

[0120] In some embodiments, the rAAV sample is initially incubated at a temperature of about 10° C., about 9° C., about 8° C., about 7° C., about 6° C., about 5° C., about 4° C., about 3° C., about 2° C., about 1° C., or about 0° C. The incubation time can be maintained for a period of about 10 minutes to about 120 minutes or longer. In some embodiments, the rAAV sample is initially incubated for a period of 10 minutes, 20 minutes, 30 minutes, 40 minutes, 50 minutes, 60 minutes, 70 minutes, 80 minutes, 90 minutes, 100 minutes, 110 minutes, or 120 minutes or longer.

[0121] During lyophilization, the temperature of the composition (e.g., rAAV sample) can be reduced, for example, to a temperature below the freezing point of water in the composition. For example, during freezing as part of the lyophilization process, the temperature of the composition can be reduced to 0°C or less, or -5°C or less, or -10°C or less, or -15°C or less, or -20°C or less, or -25°C or less, or -30°C or less, or -35°C or less, or -40°C or less, or -45°C or less, or -50°C or less, or -55°C or less, or -60°C or less, or -65°C or less, or -70°C or less. In various embodiments, the rAAV sample is maintained at a freezing temperature (e.g., -45°C) for a period of about 10 minutes, 15 minutes, 20 minutes, 25 minutes, 30 minutes, 35 minutes, 40 minutes, 45 minutes, 50 minutes, 55 minutes, 60 minutes, 65 minutes, 70 minutes, 75 minutes, 80 minutes, 85 minutes, 90 minutes, or longer.

[0122] In some embodiments, annealing is performed at a temperature of about -10° C. to about -30° C. In some cases, annealing is performed at a temperature of about -10° C., about -11° C., about -12° C., about -13° C., about -14° C., about -15° C., about -16° C., about -17° C., about -18° C., about -19° C., about -20° C., about -21° C., about -22° C., about -23° C., about -24° C., about -25° C., about -26° C., about -27° C., about -28° C., about -29° C., or about -30° C. In various embodiments, the sample is maintained at the annealing temperature for a period of about 3 hours to about 9 hours or more. In some cases, the sample is maintained at the annealing temperature for a period of about 3 hours, about 3.5 hours, about 4 hours, about 4.5 hours, about 5 hours, about 5.5 hours, about 6 hours, about 6.5 hours, about 7 hours, about 7.5 hours, about 8 hours, about 8.5 hours, or about 9 hours, or longer.

[0123] In some embodiments, additional freezing is performed after annealing. In various embodiments, the additional freezing can be performed at a temperature discussed above or herein for a period of time. For example, the rAAV sample can be lowered to about -45°C for a period of about 60 minutes.

[0124] Primary drying can be performed as part of a lyophilization process at a temperature of about -10°C to about -50°C, a pressure of about 1 mTorr to about 10 Torr, and for a period of about 10 hours to about 200 hours or longer.

[0125] In some embodiments, the primary drying is carried out at a temperature of about -20°C to about -30°C. In various embodiments, the primary drying is carried out at a temperature of about -10°C, about -11°C, about -12°C, about -13°C, about -14°C, about -15°C, about -16°C, about -17°C, about -18°C, about -19°C, about -20°C, about -21°C, about -22°C, about -23°C, about -24°C, about -25°C, about -26°C, about -27°C, about -28°C, about -29°C, or about -30°C. In some cases, the primary drying is carried out at a temperature of about -25°C. In some cases, the primary drying is carried out at a temperature of about -26°C. In some cases, the primary drying is carried out at a temperature of about -27°C.

[0126] In some embodiments, the pressure around the composition during the initial drying is reduced to below the standard atmospheric pressure. For example, the pressure around the composition can be reduced to 100 torr or lower, or 10 torr or lower, or 1 torr or lower, or 500 millitorr or lower, or 400 millitorr or lower, or 300 millitorr or lower, or 200 millitorr or lower, or 100 millitorr or lower, or 90 millitorr or lower, or 80 millitorr or lower, or 70 millitorr or lower, or 60 millitorr or lower, or 50 millitorr or lower, or 40 millitorr or lower, or 30 millitorr or lower, or 20 millitorr or lower, or 10 millitorr or lower, or 5 millitorr or lower or 1 millitorr or lower. In some cases, the pressure around the composition is reduced to about 40 millitorr to about 60 millitorr or lower. In some cases, the pressure around the composition is reduced to about 45 millitorr to about 55 millitorr or lower. In some cases, the pressure around the composition is reduced to about 50 millitorr.

[0127] In a plurality of embodiments, the first drying is carried out for about 10 hours to about 200 hours or longer time period. In some cases, the first drying is carried out for about 10 hours, about 15 hours, about 20 hours, about 25 hours, about 30 hours, about 35 hours, about 40 hours, about 45 hours, about 50 hours, about 55 hours, about 60 hours, about 65 hours, about 70 hours, about 75 hours, about 80 hours, about 85 hours, about 90 hours, about 95 hours, about 100 hours, about 120 hours, about 140 hours, about 160 hours, about 180 hours or about 200 hours or longer time period. In some cases, the first drying is carried out for about 40 hours to about 60 hours time period. In some cases, the first drying is carried out for about 45 hours to about 55 hours time period. In some cases, the first drying is carried out for about 50 hours time period.

[0128] Secondary drying can be performed as part of a lyophilization process at a temperature of about 5°C to about 65°C, a pressure of about 1 mTorr to about 10 Torr, and for a period of about 1 hour to about 30 hours or longer.

[0129] In some embodiments, secondary drying is performed at a temperature of about 20° C. to about −50° C. In various embodiments, secondary drying is performed at a temperature of about 10° C., about 11° C., about 12° C., about 13° C., about 14° C., about 15° C., about 16° C., about 17° C., about 18° C., about 19° C., about 20° C., about 21° C., about 22° C., about 23° C., about 24° C., about 25° C., about 26° C., about 27° C., about 28° C., about 29° C., about 30° C., about 31° C., about 32° C., about 33° C., about 34° C., about 35° C., about 36° C., about 37° C., about 38° C., about 39° C., about 40° C., about 41° C., about 42° C., about 43° C., about 44° C., about 45° C., about 46° C., about 47° C., about 48° C., about 49° C., or about 50° C. In some cases, secondary drying is performed at a temperature of about 30° C. to about 40° C. In some cases, secondary drying is performed at a temperature of about 35° C.

[0130] In some embodiments, the pressure around the composition is reduced to below the standard atmospheric pressure during the secondary drying. For example, the pressure around the composition can be reduced to 100 torr or lower, or 10 torr or lower, or 1 torr or lower, or 500 millitorr or lower, or 400 millitorr or lower, or 300 millitorr or lower, or 200 millitorr or lower, or 100 millitorr or lower, or 90 millitorr or lower, or 80 millitorr or lower, or 70 millitorr or lower, or 60 millitorr or lower, or 50 millitorr or lower, or 40 millitorr or lower, or 30 millitorr or lower, or 20 millitorr or lower, or 10 millitorr or lower, or 5 millitorr or lower or 1 millitorr or lower. In some cases, the pressure around the composition is reduced to about 150 millitorr to about 50 millitorr or lower. In some cases, the pressure around the composition is reduced to about 125 millitorr to about 75 millitorr or lower. In some cases, the pressure around the composition is reduced to about 100 millitorr.

[0131] In a plurality of embodiments, secondary drying is carried out for about 1 hour to about 30 hours or longer time period.In some cases, initial drying is carried out for about 1 hour, about 2 hours, about 3 hours, about 4 hours, about 5 hours, about 6 hours, about 7 hours, about 8 hours, about 9 hours, about 10 hours, about 11 hours, about 12 hours, about 13 hours, about 14 hours, about 15 hours, about 16 hours, about 17 hours, about 18 hours, about 19 hours, about 20 hours, about 21 hours, about 22 hours, about 23 hours, about 24 hours, about 25 hours, about 26 hours, about 27 hours, about 28 hours, about 29 hours or about 30 hours or longer time period.In some cases, initial drying is carried out for about 5 hours to about 20 hours time period.In some cases, initial drying is carried out for about 10 hours time period.In some cases, initial drying is carried out for about 15 hours time period.

[0132] In the freeze-drying process, when changing from one temperature to another temperature, the temperature change rate can be about 0.5 ° C / minute. In multiple embodiments, the temperature change rate can be about 0.1 ° C / minute, about 0.2 ° C / minute, about 0.3 ° C / minute, about 0.4 ° C / minute, about 0.5 ° C / minute, about 0.6 ° C / minute, about 0.7 ° C / minute, about 0.8 ° C / minute, about 0.9 ° C / minute or about 1 ° C / minute. In some cases, the temperature change rate can be about 2 ° C / minute, about 3 ° C / minute, about 4 ° C / minute or about 5 ° C / minute.

[0133] In various embodiments, the lyophilization process produces a lyophilized composition having a low moisture content (eg, less than 3% moisture). In various embodiments, the lyophilized composition has a moisture content of 3.0% or less, 2.9% or less, 2.8% or less, 2.7% or less, 2.6% or less, 2.5% or less, 2.4% or less, 2.3% or less, 2.2% or less, 2.1% or less, 2.0% or less, 1.9% or less, 1.8% or less, 1.7% or less, 1.6% or less, 1.5% or less, 1.4% or less, 1.3% or less, 1.2% or less, 1.1% or less, 1.0% or less, 0.9% or less, 0.8% or less, 0.7% or less, 0.6% or less, 0.5% or less, 0.4% or less, 0.3% or less, 0.2% or less, or 0.1% or less as measured by Karl Fischer (KF) titration or another method (e.g., as described below). In some embodiments, the lyophilized composition has a moisture content of about 0.5% to about 0.8%, as measured by Karl Fischer titration or another method (e.g., as described below). In some embodiments, the lyophilized composition has a moisture content of 0.5%, 0.55%, 0.6%, 0.65%, 0.7%, 0.75% or 0.8%, as measured by Karl Fischer titration or another method (e.g., as described below). In certain embodiments, the lyophilized composition has 3% or less water, as measured by Karl Fischer titration. In certain embodiments, the lyophilized composition has 2% or less water, as measured by Karl Fischer titration. In certain embodiments, the lyophilized composition has 1.5% or less water, as measured by Karl Fischer titration. In certain embodiments, the lyophilized composition has 1% or less water, as measured by Karl Fischer titration. In certain embodiments, the lyophilized composition has 0.9% or less water, as measured by Karl Fischer titration. In certain embodiments, the lyophilized composition has 0.8% or less water, as measured by Karl Fischer titration. In certain embodiments, the lyophilized composition has 0.7% or less water, as measured by Karl Fischer titration. In certain embodiments, the lyophilized composition has 0.6% or less water, as measured by Karl Fischer titration. In certain embodiments, the lyophilized composition has 0.5% or less water, as measured by Karl Fischer titration. In certain embodiments, the lyophilized composition has 0.4% or less water, as measured by Karl Fischer titration. In certain embodiments, the lyophilized composition has 0.3% or less water, as measured by Karl Fischer titration. In certain embodiments, the lyophilized composition has 0.2% or less water, as measured by Karl Fischer titration.Other methods for determining the moisture content of a composition include, but are not limited to, loss on drying (LOD) (measuring the amount of water and volatile matter in a sample when the sample is dried under specific conditions), electrolytic sensors (e.g., using a P2O5 sensor), piezoelectric adsorption, oxide sensors, alumina sensors, absorption spectroscopy, and near infrared (NIR).

[0134] Due to the low water content of the freeze-dried composition as described above, the freeze-dried composition can be in solid form. In some cases, the solid freeze-dried composition is a powder. In some cases, the freeze-dried composition can be conducive to the long-term storage of the composition (for example, compared with the liquid preparation of the same composition). For example, the freeze-dried composition can be a storage-stable composition, wherein the composition is substantially stable over a long period of time, as discussed above or herein.

[0135] The reconstructed composition (e.g., reconstructed drug product) prepared by reconstructing the lyophilized composition is also included in the scope of the present disclosure.This reconstructed composition can be applied to a subject, for example, by injection or intravenous administration to a subject.In some embodiments, before the reconstructed composition is applied to a subject, a solid lyophilized composition (e.g., a solid lyophilized composition as described above) can be combined with a liquid to provide a liquid composition suitable for application (e.g., by injection or intravenous administration).In some cases, before the composition is applied to a subject, a solid lyophilized composition can be combined with water (e.g., water for injection, WFI) or a buffer / buffer (e.g., a buffer / buffer as described above) to provide an aqueous composition suitable for application (e.g., by injection or intravenous administration).For example, a lyophilized composition can be reconstructed with water (e.g., water for injection, WFI) or a buffer / buffer (e.g., a buffer / buffer as described above) to produce a reconstructed dosage unit suitable for application (e.g., by injection or intravenous administration) to a subject.

[0136] In various embodiments, the reconstituted dosage unit has a pH that is compatible with physiological conditions. In some cases, the pH of the reconstituted dosage unit is in the range of 6 to 8. In some cases, the pH of the reconstituted dosage unit is in the range of 6.5 to 7.5. For example, the pH of the reconstituted dosage unit can be in the range of 7 to 7.5. In some cases, the pH of the reconstituted dosage unit is 7.0. In some cases, the pH of the reconstituted dosage unit is 7.1. In some cases, the pH of the reconstituted dosage unit is 7.2. In some cases, the pH of the reconstituted dosage unit is 7.3. In some cases, the pH of the reconstituted dosage unit is 7.4. In some cases, the pH of the reconstituted dosage unit is 7.5.

[0137] The reconstituted dosage unit can contain a predetermined number of rAAV particles of the present disclosure, which is calculated in an amount sufficient to produce the desired therapeutic effect in the subject. The amount of rAAV particles in the reconstituted dosage unit administered to the subject can depend on the subject being treated, the severity of the disease, and the mode of administration. For example, the reconstituted dosage unit can contain a certain number of rAAV particles administered in a therapeutically effective amount as disclosed herein.

[0138] The reconstruction of the lyophilized composition discussed herein can be achieved in 1 minute or less. In some cases, the reconstruction of the lyophilized composition is achieved in 30 seconds or less. In some cases, the reconstruction of the lyophilized composition is achieved in 20 seconds or less. In some cases, the reconstruction of the lyophilized composition is achieved in 15 seconds or less. In multiple embodiments, the reconstruction of the lyophilized composition is achieved in 60 seconds or less, 55 seconds or less, 50 seconds or less, 45 seconds or less, 40 seconds or less, 35 seconds or less, 30 seconds or less, 25 seconds or less, 20 seconds or less, 15 seconds or less, 10 seconds or less or 5 seconds or less. In exemplary aspects, the reconstructed composition is free of or substantially free of visible particles.

[0139] Stability of formulations and compositions

[0140] The pharmaceutical preparations and compositions of the present invention exhibit a high level of stability. The term "stable" as used herein with reference to a pharmaceutical preparation means that the AAV particles in the pharmaceutical preparation retain an acceptable degree of structure and / or function and / or biological activity after storage for a defined amount of time. A preparation can be stable even if the AAV particles contained therein do not maintain 100% of their pre-storage structure and / or function and / or biological activity after storage for a defined amount of time. In some cases, the structure and / or function and / or biological activity of the AAV particles after storage for a defined amount of time remains about 90%, about 95%, about 96%, about 97%, about 98% or about 99% can be considered "stable".

[0141] Reference to the stability of a pharmaceutical formulation or composition "after" a specified period of time is intended to mean that the stability parameter (e.g., % complete capsid, vector genome titer, or average particle size) is measured at or about the end of the specific period of time, and is not intended to mean that the pharmaceutical formulation or composition must maintain the same degree of stability for the measured parameter thereafter. For example, reference to a specific stability after 6 months means that the stability measurement was performed at the beginning of the study or about 6 months later. Other methods for assessing the stability of AAV particles in formulations (including lyophilized compositions) are described in the following examples.

[0142] The storage stability of a lyophilized composition can be assessed by reconstitution of a composition prepared from the lyophilized composition after storage for a defined amount of time.

[0143] In some cases, the stable lyophilized composition has an average particle size of about 20nm to about 40nm after reconstruction (e.g., as a reconstructed drug product), as determined by dynamic light scattering. In some cases, the average particle size is about 25nm to about 35nm, as determined by dynamic light scattering. In multiple embodiments, the average particle size is equal to or not greater than about 20nm, about 21nm, about 22nm, about 23nm, about 24nm, about 25nm, about 26nm, about 27nm, about 28nm, about 29nm, about 30nm, about 31nm, about 32nm, about 33nm, about 34nm, about 35nm, about 36nm, about 37nm, about 38nm, about 39nm or about 40nm, as determined by dynamic light scattering.

[0144] In some cases, the stable lyophilized composition has an average particle size after reconstitution (e.g., as a reconstituted drug product) that changes by no more than about 10%, about 9%, about 8%, about 7%, about 6%, about 5%, about 4%, about 3%, about 2%, or about 1% relative to the average particle size of the composition before lyophilization, as determined by dynamic light scattering after storage for a certain period of time.

[0145] In some cases, the stable lyophilized composition comprises a group of rAAV particles after reconstitution (e.g., as a recombinant drug product), the rAAV particles comprising at least 80% complete capsids, as determined by anion exchange chromatography (e.g., AEX-UPLC). In some cases, the stable lyophilized composition comprises a group of rAAV particles after reconstitution, the rAAV particles comprising at least 95% complete capsids, as determined by AEX-UPLC. In some cases, the group of rAAV particles comprises or includes at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% complete capsids, as determined by AEX-UPLC.

[0146] In some cases, the stable lyophilized composition comprises, upon reconstitution (e.g., as a recombinant drug product), a population of rAAV particles comprising a percentage of complete capsids, as determined by AEX-UPLC, wherein the percentage of complete capsids in the reconstituted composition is within 10% of the percentage of complete capsids in the drug formulation prior to lyophilization. In some cases, the percentage of complete capsids in the reconstituted drug product is within 2% of the percentage of complete capsids in the drug formulation prior to lyophilization. In some cases, the percentage of complete capsids in the reconstituted drug product is within 1% of the percentage of complete capsids in the drug formulation prior to lyophilization. In some cases, the percentage of complete capsids in the reconstituted drug product is within 0.5% of the percentage of complete capsids in the drug formulation prior to lyophilization. In various embodiments, the percentage of complete capsid in the reconstituted drug product is within 10%, within 9%, within 8%, within 7%, within 6%, within 5%, within 4.5%, within 4%, within 3.5%, within 3%, within 2.5%, within 2%, within 1.5%, within 1%, within 0.75%, within 0.5%, or within 0.25% of the percentage of complete capsid in the pre-lyophilized drug formulation as determined by AEX-UPLC.

[0147] In some cases, the stable lyophilized composition has a vector genome titer after reconstitution (e.g., as a reconstituted drug product), as determined by droplet digital polymerase chain reaction (ddPCR), which is within 10% of the vector genome titer present in the drug formulation before lyophilization. In some cases, the vector genome titer is within 7% of the vector genome titer present in the pre-lyophilized formulation. In some cases, the vector genome titer is within 5% of the vector genome titer present in the pre-lyophilized formulation. In multiple embodiments, the stable lyophilized composition has a vector genome titer after reconstitution (e.g., as a recombinant drug product), as determined by ddPCR, which is within 10% of the vector genome titer present in the pre-lyophilized drug formulation, within 9%, within 8%, within 7%, within 6%, within 5%, within 4%, within 3%, within 2%, or within 1%.

[0148] In any of the above or herein discussed multiple embodiments, the storage stability of the lyophilized composition (assessed by the reconstitution composition prepared from the lyophilized composition) can be measured after storing a limited time period at a specified temperature. In some cases, the time period is 1 month. In some cases, the time period is 3 months. In some cases, the time period is 6 months. In multiple embodiments, the time period is 2 days, 3 days, 4 days, 5 days, 6 days, 1 week, 2 weeks, 3 weeks, 1 month, 2 months, 3 months, 4 months, 5 months, 6 months, 7 months, 8 months, 9 months, 10 months, 11 months, 12 months, 15 months, 18 months, 21 months, 24 months, 30 months, 36 months, 42 months, 48 ​​months or 5 years or longer. In various embodiments, the stability parameters can be measured after storage for a period of time (as discussed above) at a temperature of -30°C, -20°C, -10°C, -5°C, 0°C, 2°C-8°C, 5°C, 10°C, 15°C, 20°C, or 25°C. In some cases, the storage period and temperature are 1 month at a temperature of 2°C-8°C. In some cases, the storage period and temperature are 3 months at a temperature of 2°C-8°C. In some cases, the storage period and temperature are 6 months at a temperature of 2°C-8°C.

[0149] In some cases, a stable lyophilized composition has storage parameters as discussed above or herein after reconstitution (e.g., as a reconstituted drug product) that remain the same or substantially the same as the parameters measured in the formulation prior to lyophilization.

[0150] Exemplary Formulations and Compositions

[0151] According to one aspect of the invention, a pharmaceutical formulation comprises (i) recombinant adeno-associated virus (rAAV) particles, (ii) a buffer at a concentration of about 1 mM to about 20 mM, (iii) a first salt at a concentration of about 10 mM to about 50 mM, (iv) a second salt at a concentration of about 20 mM to 100 mM, (v) a sugar at a concentration of about 1% w / v to about 10% w / v, (vi) a filler at a concentration of about 1% w / v to about 6% w / v, and (vii) a surfactant at a concentration of about 0.001% w / v to about 0.1% w / v, wherein the formulation has a pH of about 6.8 to about 7.8.

[0152] In some cases, a pharmaceutical formulation comprises (i) recombinant adeno-associated virus (rAAV) particles, (ii) Tris buffer at a concentration of 5 mM to 15 mM, (iii) sodium chloride at a concentration of 20 mM to 40 mM, (iv) L-arginine hydrochloride at a concentration of 30 mM to 90 mM, (v) sucrose at a concentration of 3% w / v to 7% w / v, (vi) mannitol at a concentration of 2% w / v to 5% w / v, and (vii) polysorbate 80 or poloxamer 188 at a concentration of 0.005% w / v to 0.015% w / v, wherein the formulation has a pH of 7.1 to 7.5.

[0153] In some cases, the pharmaceutical formulation comprises (i) recombinant adeno-associated virus (rAAV) particles selected from the group consisting of AAV1 serotype, AAV2 serotype, AAV3 serotype, AAV4 serotype, AAV5 serotype, AAV6 serotype, AAV7 serotype, AAV8 serotype, AAV9 serotype, and AAV10 serotype, (ii) Tris buffer at a concentration of 5 mM to 15 mM, (iii) chlorine The invention relates to a method for preparing an aqueous solution of at least one hydroxypropyl iodide (hydroxypropyl iodide) and a preparation of at least one hydroxypropyl iodide. The method comprises: (a) preparing an aqueous solution of at least one hydroxypropyl iodide (hydroxypropyl iodide) and a preparation of at least one hydroxypropyl iodide. The method comprises: (a) preparing an aqueous solution of at least one hydroxypropyl iodide (hydroxypropyl iodide) and a preparation of at least one hydroxypropyl iodide. The method comprises: (a) preparing an aqueous solution of at least one hydroxypropyl iodide (hydroxypropyl iodide) and a preparation of at least one hydroxypropyl iodide.

[0154] In some cases, a pharmaceutical formulation comprises (i) recombinant adeno-associated virus (rAAV) particles of serotype AAV1, (ii) Tris buffer at a concentration of 5 mM to 15 mM, (iii) sodium chloride at a concentration of 20 mM to 40 mM, (iv) L-arginine hydrochloride at a concentration of 30 mM to 90 mM, (v) sucrose at a concentration of 3% w / v to 7% w / v, (vi) mannitol at a concentration of 2% w / v to 5% w / v, and (vii) polysorbate 80 or poloxamer 188 at a concentration of 0.005% w / v to 0.015% w / v, wherein the formulation has a pH of 7.1 to 7.5.

[0155] In some cases, a pharmaceutical formulation comprises (i) recombinant adeno-associated virus (rAAV) particles of serotype AAV5, (ii) Tris buffer at a concentration of 5 mM to 15 mM, (iii) sodium chloride at a concentration of 20 mM to 40 mM, (iv) L-arginine hydrochloride at a concentration of 30 mM to 90 mM, (v) sucrose at a concentration of 3% w / v to 7% w / v, (vi) mannitol at a concentration of 2% w / v to 5% w / v, and (vii) polysorbate 80 or poloxamer 188 at a concentration of 0.005% w / v to 0.015% w / v, wherein the formulation has a pH of 7.1 to 7.5.

[0156] In some cases, a pharmaceutical formulation comprises (i) recombinant adeno-associated virus (rAAV) particles of serotype AAV8, (ii) Tris buffer at a concentration of 5 mM to 15 mM, (iii) sodium chloride at a concentration of 20 mM to 40 mM, (iv) L-arginine hydrochloride at a concentration of 30 mM to 90 mM, (v) sucrose at a concentration of 3% w / v to 7% w / v, (vi) mannitol at a concentration of 2% w / v to 5% w / v, and (vii) polysorbate 80 or poloxamer 188 at a concentration of 0.005% w / v to 0.015% w / v, wherein the formulation has a pH of 7.1 to 7.5.

[0157] In some cases, a pharmaceutical formulation comprises (i) recombinant adeno-associated virus (rAAV) particles of serotype AAV9, (ii) Tris buffer at a concentration of 5 mM to 15 mM, (iii) sodium chloride at a concentration of 20 mM to 40 mM, (iv) L-arginine hydrochloride at a concentration of 30 mM to 90 mM, (v) sucrose at a concentration of 3% w / v to 7% w / v, (vi) mannitol at a concentration of 2% w / v to 5% w / v, and (vii) polysorbate 80 or poloxamer 188 at a concentration of 0.005% w / v to 0.015% w / v, wherein the formulation has a pH of 7.1 to 7.5.

[0158] In some cases, the pharmaceutical formulation comprises (i) recombinant adeno-associated virus (rAAV) particles, (ii) Tris buffer at a concentration of 10 mM ± 1 mM, (iii) sodium chloride at a concentration of 30 mM ± 3 mM, (iv) L-arginine hydrochloride at a concentration of 40 mM ± 5 mM or 80 mM ± 5 mM, (v) sucrose at a concentration of 5% w / v ± 1% w / v, (vi) mannitol at a concentration of 3.3% w / v ± 0.5% w / v, and (vii) polysorbate 80 or poloxamer 188 at a concentration of 0.01% w / v ± 0.002% w / v, wherein the formulation has a pH of 7.3 ± 0.1.

[0159] In some cases, the pharmaceutical formulation comprises (i) recombinant adeno-associated virus (rAAV) particles selected from the group consisting of AAV1 serotype, AAV2 serotype, AAV3 serotype, AAV4 serotype, AAV5 serotype, AAV6 serotype, AAV7 serotype, AAV8 serotype, AAV9 serotype, and AAV10 serotype, (ii) Tris buffer at a concentration of 10 mM ± 1 mM, (iii) sodium chloride at a concentration of The invention relates to a method for preparing an aqueous solution of at least one hydroxypropyl ester of amino acid residues having a concentration of 30 mM ± 3 mM, (iv) L-arginine hydrochloride having a concentration of 40 mM ± 5 mM or 80 mM ± 5 mM, (v) sucrose having a concentration of 5% w / v ± 1% w / v, (vi) mannitol having a concentration of 3.3% w / v ± 0.5% w / v, and (vii) polysorbate 80 or poloxamer 188 having a concentration of 0.01% w / v ± 0.002% w / v, wherein the formulation has a pH of 7.3 ± 0.1.

[0160] In some cases, a pharmaceutical formulation comprises (i) recombinant adeno-associated virus (rAAV) particles of serotype AAV1, (ii) Tris buffer at a concentration of 10 mM ± 1 mM, (iii) sodium chloride at a concentration of 30 mM ± 3 mM, (iv) L-arginine hydrochloride at a concentration of 40 mM ± 5 mM or 80 mM ± 5 mM, (v) sucrose at a concentration of 5% w / v ± 1% w / v, (vi) mannitol at a concentration of 3.3% w / v ± 0.5% w / v, and (vii) polysorbate 80 or poloxamer 188 at a concentration of 0.01% w / v ± 0.002% w / v, wherein the formulation has a pH of 7.3 ± 0.1.

[0161] In some cases, a pharmaceutical formulation comprises (i) recombinant adeno-associated virus (rAAV) particles of serotype AAV5, (ii) Tris buffer at a concentration of 10 mM ± 1 mM, (iii) sodium chloride at a concentration of 30 mM ± 3 mM, (iv) L-arginine hydrochloride at a concentration of 40 mM ± 5 mM or 80 mM ± 5 mM, (v) sucrose at a concentration of 5% w / v ± 1% w / v, (vi) mannitol at a concentration of 3.3% w / v ± 0.5% w / v, and (vii) polysorbate 80 or poloxamer 188 at a concentration of 0.01% w / v ± 0.002% w / v, wherein the formulation has a pH of 7.3 ± 0.1.

[0162] In some cases, a pharmaceutical formulation comprises (i) recombinant adeno-associated virus (rAAV) particles of serotype AAV8, (ii) Tris buffer at a concentration of 10 mM ± 1 mM, (iii) sodium chloride at a concentration of 30 mM ± 3 mM, (iv) L-arginine hydrochloride at a concentration of 40 mM ± 5 mM or 80 mM ± 5 mM, (v) sucrose at a concentration of 5% w / v ± 1% w / v, (vi) mannitol at a concentration of 3.3% w / v ± 0.5% w / v, and (vii) polysorbate 80 or poloxamer 188 at a concentration of 0.01% w / v ± 0.002% w / v, wherein the formulation has a pH of 7.3 ± 0.1.

[0163] In some cases, the pharmaceutical formulation comprises (i) recombinant adeno-associated virus (rAAV) particles of serotype AAV9, (ii) Tris buffer at a concentration of 10 mM ± 1 mM, (iii) sodium chloride at a concentration of 30 mM ± 3 mM, (iv) L-arginine hydrochloride at a concentration of 40 mM ± 5 mM or 80 mM ± 5 mM, (v) sucrose at a concentration of 5% w / v ± 1% w / v, (vi) mannitol at a concentration of 3.3% w / v ± 0.5% w / v, and (vii) polysorbate 80 or poloxamer 188 at a concentration of 0.01% w / v ± 0.002% w / v, wherein the formulation has a pH of 7.3 ± 0.1.

[0164] In some cases, a pharmaceutical formulation comprises (i) recombinant adeno-associated virus (rAAV) particles, (ii) phosphate buffer at a concentration of 5 mM to 15 mM, (iii) sodium chloride at a concentration of 20 mM to 40 mM, (iv) L-arginine hydrochloride at a concentration of 30 mM to 90 mM, (v) sucrose at a concentration of 3% w / v to 7% w / v, (vi) mannitol at a concentration of 2% w / v to 5% w / v, and (vii) polysorbate 80 or poloxamer 188 at a concentration of 0.005% w / v to 0.015% w / v, wherein the formulation has a pH of 7.1 to 7.5.

[0165] In some cases, the pharmaceutical formulation comprises (i) recombinant adeno-associated virus (rAAV) particles selected from the group consisting of AAV1 serotype, AAV2 serotype, AAV3 serotype, AAV4 serotype, AAV5 serotype, AAV6 serotype, AAV7 serotype, AAV8 serotype, AAV9 serotype, and AAV10 serotype, (ii) phosphate buffer at a concentration of 5 mM to 15 mM, (iii) chloride The invention relates to a method for preparing an aqueous solution of at least one hydroxypropyl iodide (hydroxypropyl iodide) and a preparation of at least one hydroxypropyl iodide. The method comprises: (a) preparing an aqueous solution of at least one hydroxypropyl iodide (hydroxypropyl iodide) and a preparation of at least one hydroxypropyl iodide. The method comprises: (a) preparing an aqueous solution of at least one hydroxypropyl iodide (hydroxypropyl iodide) and a preparation of at least one hydroxypropyl iodide. The method comprises: (a) preparing an aqueous solution of at least one hydroxypropyl iodide (hydroxypropyl iodide) and a preparation of at least one hydroxypropyl iodide.

[0166] In some cases, a pharmaceutical formulation comprises (i) recombinant adeno-associated virus (rAAV) particles of serotype AAV1, (ii) phosphate buffer at a concentration of 5 mM to 15 mM, (iii) sodium chloride at a concentration of 20 mM to 40 mM, (iv) L-arginine hydrochloride at a concentration of 30 mM to 90 mM, (v) sucrose at a concentration of 3% w / v to 7% w / v, (vi) mannitol at a concentration of 2% w / v to 5% w / v, and (vii) polysorbate 80 or poloxamer 188 at a concentration of 0.005% w / v to 0.015% w / v, wherein the formulation has a pH of 7.1 to 7.5.

[0167] In some cases, a pharmaceutical formulation comprises (i) recombinant adeno-associated virus (rAAV) particles of serotype AAV5, (ii) phosphate buffer at a concentration of 5 mM to 15 mM, (iii) sodium chloride at a concentration of 20 mM to 40 mM, (iv) L-arginine hydrochloride at a concentration of 30 mM to 90 mM, (v) sucrose at a concentration of 3% w / v to 7% w / v, (vi) mannitol at a concentration of 2% w / v to 5% w / v, and (vii) polysorbate 80 or poloxamer 188 at a concentration of 0.005% w / v to 0.015% w / v, wherein the formulation has a pH of 7.1 to 7.5.

[0168] In some cases, a pharmaceutical formulation comprises (i) recombinant adeno-associated virus (rAAV) particles of serotype AAV8, (ii) phosphate buffer at a concentration of 5 mM to 15 mM, (iii) sodium chloride at a concentration of 20 mM to 40 mM, (iv) L-arginine hydrochloride at a concentration of 30 mM to 90 mM, (v) sucrose at a concentration of 3% w / v to 7% w / v, (vi) mannitol at a concentration of 2% w / v to 5% w / v, and (vii) polysorbate 80 or poloxamer 188 at a concentration of 0.005% w / v to 0.015% w / v, wherein the formulation has a pH of 7.1 to 7.5.

[0169] In some cases, a pharmaceutical formulation comprises (i) recombinant adeno-associated virus (rAAV) particles of serotype AAV9, (ii) phosphate buffer at a concentration of 5 mM to 15 mM, (iii) sodium chloride at a concentration of 20 mM to 40 mM, (iv) L-arginine hydrochloride at a concentration of 30 mM to 90 mM, (v) sucrose at a concentration of 3% w / v to 7% w / v, (vi) mannitol at a concentration of 2% w / v to 5% w / v, and (vii) polysorbate 80 or poloxamer 188 at a concentration of 0.005% w / v to 0.015% w / v, wherein the formulation has a pH of 7.1 to 7.5.

[0170] In some cases, the pharmaceutical formulation comprises (i) recombinant adeno-associated virus (rAAV) particles, (ii) phosphate buffer at a concentration of 10 mM ± 1 mM, (iii) sodium chloride at a concentration of 30 mM ± 3 mM, (iv) L-arginine hydrochloride at a concentration of 40 mM ± 5 mM or 80 mM ± 5 mM, (v) sucrose at a concentration of 5% w / v ± 1% w / v, (vi) mannitol at a concentration of 3.3% w / v ± 0.5% w / v, and (vii) polysorbate 80 or poloxamer 188 at a concentration of 0.01% w / v ± 0.002% w / v, wherein the formulation has a pH of 7.3 ± 0.1.

[0171] In some cases, the pharmaceutical formulation comprises (i) recombinant adeno-associated virus (rAAV) particles selected from the group consisting of AAV1 serotype, AAV2 serotype, AAV3 serotype, AAV4 serotype, AAV5 serotype, AAV6 serotype, AAV7 serotype, AAV8 serotype, AAV9 serotype, and AAV10 serotype, (ii) phosphate buffer having a concentration of 10 mM ± 1 mM, (iii) sodium chloride having a concentration of The invention relates to a method for preparing an aqueous solution of at least one hydroxypropyl ester of amino acid residues having a concentration of 30 mM ± 3 mM, (iv) L-arginine hydrochloride having a concentration of 40 mM ± 5 mM or 80 mM ± 5 mM, (v) sucrose having a concentration of 5% w / v ± 1% w / v, (vi) mannitol having a concentration of 3.3% w / v ± 0.5% w / v, and (vii) polysorbate 80 or poloxamer 188 having a concentration of 0.01% w / v ± 0.002% w / v, wherein the formulation has a pH of 7.3 ± 0.1.

[0172] In some cases, a pharmaceutical formulation comprises (i) recombinant adeno-associated virus (rAAV) particles of serotype AAV1, (ii) phosphate buffer at a concentration of 10 mM±1 mM, (iii) sodium chloride at a concentration of 30 mM±3 mM, (iv) L-arginine hydrochloride at a concentration of 40 mM±5 mM or 80 mM±5 mM, (v) sucrose at a concentration of 5% w / v±1% w / v, (vi) mannitol at a concentration of 3.3% w / v±0.5% w / v, and (vii) polysorbate 80 or poloxamer 188 at a concentration of 0.01% w / v±0.002% w / v, wherein the formulation has a pH of 7.3±0.1.

[0173] In some cases, a pharmaceutical formulation comprises (i) recombinant adeno-associated virus (rAAV) particles of serotype AAV5, (ii) phosphate buffer at a concentration of 10 mM ± 1 mM, (iii) sodium chloride at a concentration of 30 mM ± 3 mM, (iv) L-arginine hydrochloride at a concentration of 40 mM ± 5 mM or 80 mM ± 5 mM, (v) sucrose at a concentration of 5% w / v ± 1% w / v, (vi) mannitol at a concentration of 3.3% w / v ± 0.5% w / v, and (vii) polysorbate 80 or poloxamer 188 at a concentration of 0.01% w / v ± 0.002% w / v, wherein the formulation has a pH of 7.3 ± 0.1.

[0174] In some cases, a pharmaceutical formulation comprises (i) recombinant adeno-associated virus (rAAV) particles of serotype AAV8, (ii) phosphate buffer at a concentration of 10 mM ± 1 mM, (iii) sodium chloride at a concentration of 30 mM ± 3 mM, (iv) L-arginine hydrochloride at a concentration of 40 mM ± 5 mM or 80 mM ± 5 mM, (v) sucrose at a concentration of 5% w / v ± 1% w / v, (vi) mannitol at a concentration of 3.3% w / v ± 0.5% w / v, and (vii) polysorbate 80 or poloxamer 188 at a concentration of 0.01% w / v ± 0.002% w / v, wherein the formulation has a pH of 7.3 ± 0.1.

[0175] In some cases, a pharmaceutical formulation comprises (i) recombinant adeno-associated virus (rAAV) particles of serotype AAV9, (ii) phosphate buffer at a concentration of 10 mM ± 1 mM, (iii) sodium chloride at a concentration of 30 mM ± 3 mM, (iv) L-arginine hydrochloride at a concentration of 40 mM ± 5 mM or 80 mM ± 5 mM, (v) sucrose at a concentration of 5% w / v ± 1% w / v, (vi) mannitol at a concentration of 3.3% w / v ± 0.5% w / v, and (vii) polysorbate 80 or poloxamer 188 at a concentration of 0.01% w / v ± 0.002% w / v, wherein the formulation has a pH of 7.3 ± 0.1.

[0176] In any of the various pharmaceutical formulations discussed above, the surfactant is polysorbate 80. In any of the various pharmaceutical formulations discussed above, the surfactant is poloxamer 188.

[0177] In various embodiments, the present disclosure provides a lyophilized composition prepared by lyophilizing any of the pharmaceutical formulations discussed above, or a reconstituted composition (or drug product) prepared by reconstituting any of such lyophilized compositions.

[0178] Containers, Kits, and Unit Dosage Forms

[0179] The present disclosure includes containers and kits containing or comprising a formulation or composition as discussed herein. In some cases, the container contains a pre-lyophilized pharmaceutical composition, a lyophilized composition, or a reconstituted composition or a drug product. In some cases, the container is a glass vial. The present disclosure also includes a kit comprising a container and instructions for use (e.g., therapeutic use discussed below).

[0180] In exemplary aspects, a composition comprising AAV particles as discussed herein is contained in a glass or plastic container (e.g., a glass vial or a plastic tube). In exemplary embodiments, the glass or plastic container is any of those known in the art or commercially available. In some cases, the disclosure includes placing about 0.1 ml to about 25 ml (e.g., about 1 ml to about 10 ml) of a composition comprising AAV particles in a glass or plastic container.

[0181] Providing composition in container can be conducive to maintaining composition as sterile composition.For example, container can be configured to maintain the composition enclosed in container in aseptic environment.Therefore, container can be sealed container, for example container can include seal, such as waterproof seal and / or airtight seal.Seal can be removed from container, to allow user to obtain the content of container.In some cases, seal can be fragile seal, or in other cases, seal can be configured to allow needle, sleeve or syringe to insert container interior without removing seal from container.In some cases, seal is configured to allow to obtain container interior material when seal is not removed from container, and this seal can be conducive to maintaining the content of container (for example, composition in container) in aseptic environment before composition is applied to subject.Suitable sealing material includes for example rubber or polymer seal, such as, but not limited to silicone rubber, natural rubber, styrene butadiene rubber, ethylene-propylene copolymer, polychloroprene, polyacrylate, polybutadiene, polyurethane, styrene butadiene etc., and their combination.For example, in certain embodiments, seal is the diaphragm that can be pierced by needle, syringe or sleeve. The seal can also provide convenient access to the sample in the container, as well as provide a protective barrier over the container opening. In some cases, the seal is a removable seal, such as a threaded cap or snap-on cap or other suitable sealing element that can be applied to the container opening. For example, the threaded cap can be screwed onto the opening before or after the sample is added to the container.

[0182] In some cases, the container is a unit dose container. A unit dose container refers to a container for containing one or more monolithic doses applied to a subject. In some embodiments, a unit dose container contains a predetermined number of subject compositions, which are calculated in an amount sufficient to produce a desired effect in a subject. Certain embodiments of the composition can be provided in a unit dose container suitable for a single administration of an exact dose. The amount of the active composition applied to a subject can depend on the subject being treated, the severity of the disease, and the mode of administration. For example, a unit dose container can contain a certain number of compositions as disclosed herein for administration, and the amount of the composition can effectively achieve the desired effect in the subject being treated. In some cases, a unit dose container contains a composition with a therapeutically effective amount of AAV. In certain embodiments, a unit dose container is a vial. In some cases, a vial is a sealed vial (e.g., as described above for a sealed container).

[0183] The container can be composed of any convenient material that is compatible with the AAV and other components of the composition. For example, the container can be a solid compatible container configured to hold a solid (e.g., a lyophilized composition). In some cases, the container is a liquid compatible container configured to hold a liquid. The container can also be solid and liquid compatible, wherein the container is configured to hold a solid and a liquid. In some cases, the liquid in the container can be an aqueous liquid, and in these cases, the container can be compatible with the aqueous composition. By "compatibility" is meant that the container is substantially inert (e.g., the liquid and / or composition or other components that do not contact the container react significantly). Examples of suitable container materials include, but are not limited to, glass and plastic. For example, the container can be composed of glass, such as, but not limited to, silicate glass, borosilicate glass, sodium borosilicate glass, fused silica glass, fused silica glass, and the like. Other examples of container materials suitable for the container include plastics such as, but not limited to, polypropylene, polymethylpentene, polytetrafluoroethylene (PTFE), perfluoroether (PFE), fluorinated ethylene propylene (FEP), perfluoroalkoxyalkane (PFA), polyethylene terephthalate (PET), polyethylene (PE), polyetheretherketone (PEEK), polystyrene, etc. In some cases, as described above, the container is a vial, and thus can be a glass vial. As described above, the container can be a sealed container, and thus can be a sealed glass vial.

[0184] In exemplary aspects, the volume of the composition comprising the AAV placed in the glass or plastic container is about 0.1 to about 25 ml, about 0.1 ml to about 10 ml, about 0.1 ml to about 5 ml, about 0.2 ml to about 6 ml, about 0.2 ml to about 5 ml, about 0.25 ml to about 5 ml, about 2 ml to about 5 ml, about 2.5 ml to about 5 ml, about 3 ml to about 5 ml, about 4 ml to about 5 ml, about 5 ml to about 10 ml, about 6 ml, about 9 ml, or about 7 ml to about 8 ml. In some cases, the volume is about 0.1 ml, about 0.2 ml, about 0.25 ml, about 0.3 ml, about 0.4 ml, about 0.5 ml, about 0.6 ml, about 0.7 ml, about 0.75 ml, about 0.8 ml, about 0.9 ml, about 1 ml, about 2 ml, about 2.5 ml, about 3 ml, about 3.5 ml, about 4 ml, about 4.5 ml, about 5 ml, about 5.5 ml, about 6 ml, about 6.5 ml, about 7 ml, about 7.5 ml, about 8 ml, about 8.5 ml, about 9 ml, about 9.5 ml or about 10 ml.

[0185] Therapeutic Uses

[0186] The pharmaceutical preparations and compositions of the present invention can be used, in particular, to treat, prevent and / or ameliorate any disease or condition that can be treated by gene therapy. In an exemplary embodiment, the pharmaceutical compositions discussed herein can be administered to a subject in an amount that is effective in treating a condition.

[0187] The compositions disclosed herein can be formulated for administration by known methods, such as intravenous administration (e.g., bolus injection or continuous infusion for a period of time) or by injection. In certain embodiments, the AAV preparations provided herein can be administered systemically or locally. Systemic administration includes, but is not limited to, intravenous administration. Local administration includes, but is not limited to, subcutaneous injection and intramuscular injection.

[0188] When administered to a subject, the liquid or reconstituted dosage unit can contain a therapeutically effective amount of AAV such that the reconstituted dosage unit delivers 1E10 viral genomes (or vector genomes) per milliliter (vg / ml) to 5E15 vg / ml.

[0189] In certain embodiments, the administration of a liquid or reconstituted dosage unit to a subject is performed according to a treatment regimen. For example, in some cases, the subject receiving treatment may have obtained a treatment regimen from a healthcare provider. In some cases, the treatment regimen includes a single administration of a dosage unit. In general, a subject receiving an AAV drug product will produce anti-drug antibodies to the AAV serotype administered to the subject, thereby preventing the additional administration of the drug product from producing a therapeutic effect. This does not exclude the possibility that different AAV serotypes can be used to perform additional administration of the same target gene contained in the rAAV drug product.

[0190] In certain embodiments, the recombinant dosage unit of the present disclosure can be used before, at the same time or after other active agents for treating related or unrelated diseases, for example, combined therapy. The example of such additional therapy includes radiotherapy, surgical therapy and chemotherapy. If provided simultaneously with other active agents, the reconstructed dosage unit of the present disclosure can be provided with the same or different preparations. For example, synchronous therapy can be achieved by administering a reconstructed dosage unit and a pharmaceutical composition with at least one other active agent (such as a chemotherapeutic agent) according to a specific treatment regimen, and the pharmaceutical composition provides a therapeutically effective dose in a combined manner. The administration of a separate pharmaceutical composition can be performed simultaneously or at different times (for example, in sequence, in any order, on the same day or on different days), as long as the combination of these substances produces a therapeutically effective effect in the subject receiving therapy.

[0191] Therefore, aspects of the present disclosure also include combination therapy. So-called combination therapy means that AAV compositions (e.g., AAV compositions as described herein) can be used in combination with another therapeutic agent to treat a single disease or condition. In certain embodiments, the AAV preparations or compositions of the present disclosure can be administered simultaneously with another therapeutic agent. In certain embodiments, the AAV preparations or compositions of the present disclosure can be administered before or after administration of another therapeutic agent. In certain embodiments, combination therapy comprises two or more AAV compositions having different serotypes and / or containing different target genes.

[0192] Example

[0193] The following examples are provided to provide a person of ordinary skill in the art with a complete disclosure and description of how to prepare and use the methods and compositions of the present invention, and are not intended to limit the scope of what the inventors consider to be their invention. Efforts have been made to ensure the accuracy of the numbers used (e.g., amounts, temperatures, etc.), but certain experimental errors and deviations should be considered. Unless otherwise indicated, parts are parts by weight, molecular weights are average molecular weights, temperatures are in degrees Celsius, and pressures are at or near atmospheric pressure.

[0194] Example 1: Pre-lyophilization formulation screening study

[0195] This study was designed to screen potential formulations suitable for lyophilization and liquid stability at 25°C for up to 2 days.

[0196] Approximately 3 mL of each of the formulations shown in Table 1 was prepared. Each formulation was filter sterilized using a 0.2 μm filter in a laminar flow hood and then dispensed into 2R RTU glass vials with a target fill volume of 0.7 mL. All vials were sealed with rubber stoppers. At least two vials of each formulation were prepared.

[0197] Table 1: Preparation

[0198]

[0199] Particle size distribution was measured by dynamic light scattering (DLS) on a Zetasizer Ultra system (Malvern, Westborough, MA) using 90 degree side scattering and a ZEN2112 low volume quartz cuvette. Five replicate measurements were collected per sample, with 10 acquisitions per replicate, each lasting 10 seconds.

[0200] The data show that sucrose and mannitol are compatible with AAV8 and do not induce the formation of AAV8 aggregates. Formulations F1, F4 and F7 all showed comparable dynamic light scattering (DLS) results (about 25nn) at t = 0 and t = 2 days at 25°C and 60% relative humidity (other samples showed possible reversible aggregation). DLS measurements showed that all formulations remained stable after exposure to 25°C / 60% RH for 2 days. In addition, no apparent recovery loss (measured by ddPCR) or purity change (measured by AEX-UPLC of the ratio of empty capsids to complete capsids) was observed after incubation of formulation F7 at 25°C / 60% RH for 2 days.

[0201] Example 2: Freeze-drying feasibility study

[0202] This study was designed to evaluate the lyophilization process feasibility of seven formulations proposed for AAV8 lyophilization process development.

[0203] Sucrose was used as a cryoprotectant and mannitol (3.3% w / v) was used as a filler. Freeze-drying design was evaluated using formulations with different levels of L-arginine hydrochloride and NaCl (0 mM, 30 mM, 50 mM and 80 mM) and two concentrations of sucrose (1.2% w / v and 5% w / v) and 0.005% w / v P188. The seven formulations evaluated in this study are shown in Table 2.

[0204] Table 2: Lyophilized formulations

[0205]

[0206] In a laminar flow hood, each formulation was filter sterilized using a 0.2 μm filter and then dispensed into 2 mL glass vials with a target fill volume of 0.4 mL. All vials were sealed with rubber stoppers. At least 10 vials were prepared for each formulation. The Tc collapse temperature or Teu eutectic temperature of each formulation will be measured by freeze drying microscopy.

[0207] The load for each lyophilization cycle contained 70 2 mL glass vials; 10 vials each for formulations F1-F7. Each formulation was grouped together. The vials were evaluated for moisture content, lyophilized cake appearance, and Tg (glass transition) analysis. Dynamic light scattering was used to detect aggregation, which is a major degradation pathway for AAV products.

[0208] The lyophilization cycle is shown in Table 3 below.

[0209] Table 3: Lyophilization cycle

[0210]

[0211]

[0212] Using FTS LyoStar TM 3 freeze dryers (SP Scientific, Stone Ridge, NY) were used to perform freeze drying experiments. As described above, ready-to-use (RTU) type I glass vials (SCHOTT, Mülheim, Germany) were placed on a freeze drying rack. Throughout the freeze drying process, a two-wire thermocouple (Omega, Norwalk, CT) was used to monitor the temperature profile of the blank control product. The sample was initially incubated at 5°C for 60 minutes, then cooled from 5°C to -45°C at a ramp rate of 0.5°C / min, and then kept at a constant temperature for 60 minutes. Annealing was performed at -20°C at a ramp rate of 0.5°C / min for 6 hours, then cooled back to -45°C at a ramp rate of 0.5°C / min, and then kept for 60 minutes. The primary drying was carried out at -26°C and 100 mTorr for 50 hours, and the secondary drying was carried out at 35°C and 100 mTorr for 10 hours, with a heating ramp rate of 0.3°C / min for both the primary and secondary drying. At the end of the freeze-drying cycle, the sample was backfilled with 80% atmospheric pressure nitrogen and the sample was dried with 13 mm The tubes were capped with chlorobutyl stoppers and sealed with 13 mm aluminum flip-top seals (West, Jersey Shore, PA).

[0213] The color and cake appearance of the lyophilized product were assessed by visual inspection.

[0214] The glass transition temperature Tg' of the maximum freeze-concentrated solution of the liquid formulation and the glass transition temperature Tg of the solid lyophilized formulation were determined on a DSC2500 (TA Instruments, New Castle, DE). To determine Tg', 40 μL of the sample solution was aspirated into a Tzero pan and fully sealed with a Tzero Hermetic cover. To determine Tg, the lyophilized samples were ground and prepared in a humidity-controlled chamber to minimize the amount of moisture that entered the sample during sample preparation. The sample powder was then transferred to a Tzero pan and fully sealed with a Tzero Hermetic cover. The sample was equilibrated at -80°C, then kept at a constant temperature for 5 minutes, and then heated to 25°C at a ramp rate of 2°C / min, adjusting 0.5°C every 60 seconds. Data analysis was performed in TRIOS.

[0215] The collapse temperature (Tc) of the formulation was determined on a Lyostat 3 freeze-drying microscope (Linkam Scientific, Waterfield, UK) equipped with a polarizing filter and an Olympus camera. Approximately 5 μL of sample solution was added to a glass cover slip, which was placed in a cooling stage under the microscope. The sample was first frozen to -45°C and then heated to 0°C at a ramp rate of 1°C / min under vacuum (100 mTorr). Images were acquired and exported using Linsys32 software and used to determine Tc.

[0216] The residual moisture content of the lyophilized samples was determined using a Vapor Pro RX moisture analyzer and a dry air generator (Arizona Instrument, Chandler, AZ). Prior to analysis, the lyophilized blocks were broken into small pieces in sealed glass vials. The air flow rate was set to 75 mL / min and the drying temperature was set to 75°C. To calculate the residual moisture content percentage, the measured residual moisture weight was divided by the weight of the lyophilized block.

[0217] Particle size distribution was measured by dynamic light scattering (DLS) on a Zetasizer Ultra system (Malvern, Westborough, MA) using 90 degree side scattering and a ZEN2112 low volume quartz cuvette. Five replicate measurements were collected per sample, with 10 acquisitions per replicate, each lasting 10 seconds. Figure 2 The results of the DLS assays for each of the seven formulations are shown. Of the seven formulations evaluated, F7 was the only formulation with the smallest change in particle size distribution profile compared to the pre-lyophilized sample.

[0218] Example 3: Buffer Screening Studies

[0219] The stability of rAAV8 formulations was evaluated using Tris buffer and sodium phosphate buffer. The average particle size for identifying aggregates was determined before and after lyophilization, the percentage of complete capsids was determined before and after lyophilization, and the titer of viral genome was determined before and after lyophilization. Lyophilization was performed as discussed in Example 2 above.

[0220] The rAAV8 capsid contains the gene of interest (GOI) for therapeutic applications. The rAAV8 vector was produced at Regeneron Pharmaceuticals (Tarrytown, NY) by triple transfection of HEK293 cells.

[0221] The sodium phosphate formulation contained 1.00E13 vg / mL rAAV8-GOI, 10 mM sodium phosphate (pH 7.3), 0.005% w / v P188, 5% w / v sucrose, 3.3% w / v mannitol, 30 mM NaCl, and 80 mM L-arginine hydrochloride. The Tris formulation contained 1.00E13 vg / mL rAAV8-GOI, 10 mM Tris buffer (pH 7.3), 0.005% w / v P188, 5% w / v sucrose, 3.3% w / v mannitol, 30 mM NaCl, and 80 mM L-arginine hydrochloride.

[0222] Particle size distribution was measured by dynamic light scattering (DLS) on a Zetasizer Ultra system (Malvern, Westborough, MA) using 90 degree side scattering and a ZEN2112 low volume quartz cuvette. Five replicate measurements were collected per sample, with 10 acquisitions per replicate, each lasting 10 seconds.

[0223] The ratio of empty capsid to complete capsid was determined by anion exchange ultra-high performance liquid chromatography (AEX-UPLC) on a Waters Acquity UPLC H-Class system (Waters, Milford, MA) equipped with a PDA and FLR detector and a CIMac AAV empty / complete 0.1 mL, 1.3 μm analytical column (BIA Separation, Slovenia). Empty capsids and complete capsids were eluted at 0.8 mL / min using a linear gradient containing Bis-Tris propane and tetramethylammonium chloride pH 8.5. Peak identification and peak integration were performed using a Waters Empower chromatography data system.

[0224] The QX200 Droplet Digital PCR (ddPCR) system (BioRad, Hercules, CA) was used to quantify vector genome titers. AAV samples were prepared in triplicate and digested with DNase I (Ambion product number AM2224) to eliminate unencapsulated DNA, and then digested with proteinase K (Invitrogen product number 25530049) to destroy the capsid. The ddPCR master mix containing primers and probe sets was then added and mixed with the reaction mixture. A 22 μL aliquot was then taken out and introduced into the droplet generator for droplet distribution. After droplet generation, the vector genome DNA contained in the droplet was amplified by PCR and analyzed on the droplet reader using QuantaSoft software.

[0225] The stability evaluation results before and after lyophilization are shown in Table 5 below.

[0226] Table 5: Stability evaluation of sodium phosphate and Tris buffers

[0227]

[0228]

[0229] The stability evaluation results showed that the Tris buffer gave superior results in the subsequent lyophilization process. It is believed that the difference in average particle size is at least partially due to the aggregation of nanobubbles in the reconstituted composition rather than AAV particles, as discussed in more detail in Example 7 below.

[0230] Example 4: Evaluation of sugar concentration and salt concentration

[0231] Sucrose concentrations, as well as NaCl and arginine hydrochloride concentrations were evaluated to determine the effect on rAAV8-GOI stability. Eight formulations were evaluated as shown in Table 6 below. Lyophilization of these eight formulations was performed as discussed in Example 2 above.

[0232] Table 6: Preparation

[0233]

[0234] Particle size distribution before and after lyophilization was measured by dynamic light scattering (DLS) on a Zetasizer Ultra system (Malvern, Westborough, MA) using 90 degree side scattering and a ZEN2112 low volume quartz cuvette. Five replicate measurements were collected per sample, with 10 acquisitions per replicate, each lasting 10 seconds.

[0235] The results are shown in Table 7 below.

[0236] Table 7: Particle size distribution of formulations before and after lyophilization

[0237]

[0238]

[0239] Formulation F7, containing 30 mM NaCl, 80 mM L-Arg HCl, and 5% sucrose, showed the least increase in particle size among the formulations tested. This formulation also exhibited good solution stability for 2 days at 25°C with no signs of aggregation. It is believed that the observed differences in particle size distribution are at least partially due to aggregation of nanobubbles rather than AAV particles in the reconstituted composition, as discussed in more detail in Example 7 below.

[0240] The residual moisture content analysis in formulation F7 after lyophilization found that the moisture content was 0.7%. The residual moisture content was determined using a Vapor Pro RX moisture analyzer and a dry air generator (Arizona Instrument, Chandler, AZ). Prior to analysis, the lyophilized block was broken into small pieces in a sealed glass vial. The air flow rate was set to 75 mL / min and the drying temperature was set to 75°C. To calculate the residual moisture content percentage, the measured residual moisture weight was divided by the weight of the lyophilized block.

[0241] The Tc and Tg' of the formulation (F7) were measured using freeze drying microscopy and DSC and were determined to be -34°C and -43°C, respectively. Fig. 6A and 6B Shown in.

[0242] like Fig.9A and 9B As shown, reducing the total ionic strength in the formulation to 80 mM resulted in a substantial decrease in the vg titer recovery rate after lyophilization (approximately 18%). Although the addition of 2 mM magnesium chloride helped to increase the vg titer recovery rate by approximately 6%, the addition failed to show a comparable stabilizing effect on the vg titer recovery rate after lyophilization compared to the effect achieved with the control formulation. This observation was unexpected because it was based on the assumption that salt may not be an effective stabilizer for proteins in lyophilized drug products because salts crystallize during freeze drying and do not remain in the amorphous matrix, which is a prerequisite for stabilizing the protein in dry form. These results confirm that salt at a total ionic strength of approximately 110 mM has a stabilizing effect on lyophilized AAV8 formulations.

[0243] Example 5: Effect of bulking agent and concentration on freeze-dried products

[0244] The effect of mannitol on the lyophilized product of rAAV8-GOI and the concentrations of mannitol, sucrose and salt were evaluated.

[0245] Formulations with and without mannitol were lyophilized and the formulations were evaluated for appearance, reconstitution time, and residual moisture content as discussed above in Example 2. Table 8 below shows the two formulations evaluated and the results of the evaluation.

[0246] Table 8: Effect of bulking agents on lyophilized formulations

[0247]

[0248]

[0249] The presence of mannitol improved the appearance of the freeze-dried cake and reduced the residual moisture content, e.g. Figure 5 shown.

[0250] The effects of different concentrations of mannitol, sucrose, NaCl, arginine hydrochloride, and MgCl2 on rAAV8-GOI formulations were also evaluated. The six formulations evaluated are shown in Table 9 below. All formulations contained 1E13 AAV8-GOI, 0.02% w / v P188, and 10 mM Tris (pH 7.3).

[0251] Table 9: Sucrose / Mannitol and Salt Screening Study Formulations

[0252]

[0253] The expected results indicate that varying the concentrations of these components can produce comparable stability results.

[0254] Example 6: Surfactant screening study

[0255] The formulation stability of rAAV8 was evaluated using different concentrations of poloxamer 188 (P188) or polysorbate 80 (PS80). The average particle size of the labeled aggregates was determined before and after lyophilization, the percentage of complete capsids was determined before and after lyophilization, and the % recovery of viral genomes was determined before and after lyophilization, as discussed above in Example 3. Lyophilization was performed as discussed above in Example 2.

[0256] In the first study, three concentrations of P188 were evaluated in a formulation containing 1E13 vg / mL rAAV8-GOI, 10 mM sodium phosphate (pH 7.3), 5% w / v sucrose, 3.3% w / v mannitol, 30 mM NaCl, and 80 mM L-Arg-HCl. The results are shown in Table 10 below.

[0257] Table 10: Effect of different concentrations of P188 on the stability of lyophilized preparations

[0258]

[0259]

[0260] In a second study, the effect of using PS80 instead of P188 was evaluated. Each formulation contained 1E13 vg / mL of rAAV8-GOI, 10 mM sodium phosphate (pH 7.3), 5% w / v sucrose, 3.3% w / v mannitol, 30 mM NaCl and 80 mM L-Arg-HCl, and either 0.005% w / v P188 or 0.005% w / v PS80. The results are shown in Table 11 below.

[0261] Table 11: Differences in surfactants

[0262]

[0263] In the third study, the recovery rate of different concentrations of surfactants was evaluated. Each formulation contained 1E13 vg / mL of rAAV8-GOI, 10 mM sodium phosphate (pH 7.3), 5% w / v sucrose, 3.3% w / v mannitol, 30 mM NaCl and 80 mM L-Arg-HCl, and had different surfactants / concentrations. Two different types of non-ionic surfactants (PS80 and P188, 0.005% w / v) and different concentrations of P188 (0.005% w / v, 0.01% w / v and 0.02% w / v) were tested. Figure 4 As shown, formulations containing 0.005% PS80 and P188 showed similar levels of recovery loss in the t=0 sample after lyophilization (91% and 90%, respectively), indicating that the observed recovery loss was not related to the specific type of non-ionic surfactant. However, increasing the concentration of surfactant from 0.005% w / v to 0.01% w / v and 0.02% w / v resulted in increased recovery after lyophilization (90%, 95% and 96%, respectively), indicating that the observed recovery loss may be due to adsorption of AAV to Type I glass vials during the freeze-drying process. The largest increase in post-lyophilization recovery was observed when the P188 concentration was increased from 0.005% to 0.01%, while further increases in surfactant concentration appeared to have little effect. Therefore, surfactant concentrations of approximately 0.01% w / v are sufficient to reduce adsorption of AAV to glass vials within the titer range tested.

[0264] Example 7: Stability of rAAV lyophilized formulations at 2°C-8°C

[0265] Six formulations (three blank controls and three rAAV8) were prepared to evaluate the stability of the lyophilized drug product over time. Lyophilization was performed as discussed above in Example 2, except that the length of secondary drying was increased to 10 hours. The formulations are identified in Table 12 below. All six formulations contained 10 mM sodium phosphate buffer (pH 7.3)

[0266] Table 12: Formulations used for long-term stability evaluation

[0267]

[0268]

[0269] The color and cake appearance of the lyophilized product were evaluated by visual inspection, and the reconstitution time was determined as discussed above in Example 2. The results are shown in Table 13 below.

[0270] Table 13: Visual appearance and reconstruction time

[0271]

[0272] The average particle size used to identify aggregates was determined before and after lyophilization as discussed above in Example 3. The results are shown in Table 14 below.

[0273] Table 14: Average particle size in the tested formulations

[0274]

[0275]

[0276] Formulation rAAV-7, which exhibited the best stability based on aggregation (Table 14), was further evaluated over a 6 month period to monitor visual appearance, particle size, % complete capsid, and titer of viral genome, as discussed above in Example 3. The results are shown in Table 15 below.

[0277] Table 15: Stability of lyophilized rAAV-7 at 5°C

[0278]

[0279] rAAV-7 (AAV8 serotype) showed good stability at 5°C for up to six months.

[0280] As described above in Examples 3 and 4, most of the observed increase in average particle size can be explained by the presence of nanobubbles in the reconstituted composition. For example, while sample rAAV-7 showed good storage stability of AAV products after lyophilization, an increase in particle size of approximately 10 nm was detected by DLS in the reconstituted rAAV-7 formulation after lyophilization compared to the formulation before lyophilization (t=0 after lyophilization, Table 15), indicating that larger sized particle species were formed during freeze drying. To investigate the root cause, a blank control sample (a formulation without AAV particles) was lyophilized and large particle species with an estimated size of approximately 100 nm to 200 nm were identified ( Figure 3 ), which is the same size range as previously observed in reconstituted lyophilized protein products (data not shown), and these nanobubbles may originate from micropores within the lyophilized cake. Since no apparent particle size increase was detected in rAAV-7 formulations up to 6 months after lyophilization, the larger sized particles formed during freeze drying may be due to nanobubbles rather than AAV aggregation. In addition, the stability results of the lyophilized rAAV-7 formulations did not show any evidence that the presence of nanobubbles in the lyophilized cake had an apparent adverse effect on the storage stability of the AAV product.

[0281] Example 8: Short-term stability of rAAV lyophilized formulations at room temperature

[0282] To support manufacturing operations (such as holding steps) prior to filling and dispensing the product into glass vials prior to lyophilization, it is desirable that the liquid lyophilized formulation remain stable for at least 48 hours at room temperature. To evaluate the solution form stability study, 0.7 mL of the AAV8 product in formulation F7 was filled into 2 mL Type I glass vials and incubated at 25°C for 2 days. Fig. 7A , 7B As shown in Figures 7 and 7C, Formulation F7 exhibited good solution form stability with no detectable changes in selected critical quality attributes (CQAs) of AAV, including particle size assessed by DLS (assessing aggregation), viral genome (vg) titer assessed by ddPCR (assessing recovery), or the ratio of empty to full capsids assessed by AEX (assessing capsid purity).

[0283] Prepare a 1×10 13 Another formulation of AAV8 at 500 vg / mL, 10 mM Tris, 30 mM sodium chloride, 80 mM L-arginine hydrochloride, 5% w / v sucrose, 3.3% w / v mannitol, and 0.01% w / v P188 (pH 7.3) was evaluated for solution stability at 25°C for 2 days and one month. The results are shown in Table 1. Fig. 10A , 10B and 10C and Fig.11A , 11B and 11C. No significant changes were observed for CQA including particle size, vg titer, and ratio of empty to full capsids. The samples were assayed for cell-based potency and no significant changes were observed (data not shown).

[0284] Example 9: Long-term stability of rAAV lyophilized formulations at 2°C-8°C

[0285] The long-term storage stability of the lyophilized AAV8 drug product in formulation F7 at 2-8°C was evaluated by lyophilized cake appearance and reconstitution time at time 0, 1, 3, 6, and 12 months (data not shown), as well as particle size, vg titer, and empty to full capsid ratio in the reconstituted AAV8 formulation. Fig. 8A , 8B No significant changes were observed in all of the above evaluations in the reconstituted formulations after lyophilization, indicating that the lyophilized AAV8 drug product in Formulation F7 is stable during long-term storage at 2-8°C for up to twelve months.

[0286] Compared with the sample at time 0 before lyophilization, the particle size increased by about 10 nm ( Fig. 8A ) can be attributed to nanobubbles, as discussed in Example 7. There is no evidence that the presence of nanobubbles significantly affects the quality or stability of the lyophilized protein product, but does affect the number of submicron particles that can be detected in reconstituted lyophilized protein formulations.

[0287] The scope of the present invention is not limited by the specific embodiments described herein. In fact, various modifications of the present invention, except those described herein, will become apparent to those skilled in the art from the foregoing description. Such modifications are intended to fall within the scope of the appended claims.

Claims

1. A pharmaceutical formulation comprising (i) recombinant adeno-associated virus (rAAV) particles, (ii) a buffer at a concentration of about 1 mM to about 20 mM, (iii) a first salt at a concentration of about 10 mM to about 50 mM, (iv) a second salt at a concentration of about 60 mM to 100 mM, (v) a sugar at a concentration of about 1% w / v to about 10% w / v, (vi) a bulking agent at a concentration of about 1% w / v to about 6% w / v, and (vii) a surfactant at a concentration of about 0.001% w / v to about 0.1% w / v, wherein the formulation has a pH of about 6.8 to about 7.

8.

2. The pharmaceutical preparation of claim 1, wherein the buffer is Tris buffer or sodium phosphate buffer.

3. The pharmaceutical formulation of claim 2, wherein the buffer is Tris buffer.

4. The pharmaceutical formulation of any one of claims 1 to 3, wherein the concentration of the buffer is 5 mM to 15 mM.

5. The pharmaceutical formulation of claim 4, wherein the concentration of the buffer is 10 mM ± 2 mM.

6. The pharmaceutical formulation of any one of claims 1 to 5, wherein the first salt is sodium chloride, potassium chloride or magnesium chloride.

7. The pharmaceutical formulation of claim 6, wherein the first salt is sodium chloride.

8. The pharmaceutical formulation of any one of claims 1 to 7, wherein the concentration of the first salt is 20 mM to 40 mM.

9. The pharmaceutical formulation of claim 8, wherein the concentration of the first salt is 30 mM ± 5 mM.

10. The pharmaceutical formulation of any one of claims 1 to 9, wherein the second salt is arginine hydrochloride.

11. The pharmaceutical formulation of any one of claims 1 to 10, wherein the concentration of the second salt is 30 mM to 90 mM.

12. The pharmaceutical formulation of claim 11, wherein the concentration of the second salt is 40 mM ± 5 mM or 80 mM ± 5 mM.

13. The pharmaceutical formulation of any one of claims 1 to 12, wherein the sugar is sucrose or trehalose.

14. The pharmaceutical formulation of claim 13, wherein the sugar is sucrose.

15. A pharmaceutical formulation as claimed in any one of claims 1 to 14, wherein the concentration of sugar is 3% w / v to 7% w / v.

16. The pharmaceutical formulation of claim 15, wherein the concentration of sugar is 5% w / v ± 1% w / v.

17. The pharmaceutical formulation of any one of claims 1 to 16, wherein the filler is mannitol or glycine.

18. The pharmaceutical formulation of claim 17, wherein the filler is mannitol.

19. The pharmaceutical formulation of any one of claims 1 to 18, wherein the concentration of the filler is 2% w / v to 5% w / v.

20. The pharmaceutical formulation of claim 19, wherein the concentration of the filler is 3.3% w / v ± 0.5% w / v.

21. The pharmaceutical formulation of any one of claims 1 to 20, wherein the surfactant is a polysorbate or a poloxamer.

22. The pharmaceutical formulation of claim 21, wherein the polysorbate is polysorbate 80.

23. The pharmaceutical formulation of claim 21, wherein the poloxamer is poloxamer 188.

24. A pharmaceutical formulation as claimed in any one of claims 1 to 23, wherein the concentration of the surfactant is from 0.001% w / v to 0.1% w / v.

25. The pharmaceutical formulation of claim 24, wherein the concentration of the surfactant is 0.01% w / v ± 0.005% w / v.

26. The pharmaceutical formulation of any one of claims 1 to 25, wherein the pH of the formulation is 7.0 to 7.

6.

27. The pharmaceutical formulation of claim 26, wherein the pH of the formulation is 7.3 ± 0.

1.

28. A pharmaceutical formulation as claimed in any one of claims 1 to 76, wherein the ratio of filler to sugar is 1:1 to 1:7 or 1:1 to 1:

3.

29. The pharmaceutical formulation of claim 28, wherein the ratio of mannitol to sucrose is 1:1 to 1:7 or 1:1 to 1:

3.

30. The pharmaceutical formulation of any one of claims 1 to 29, wherein the ratio of the first salt to the second salt is 1:1 to 1:4 31. The pharmaceutical formulation of claim 30, wherein the ratio of sodium chloride to arginine hydrochloride is 1:1 to 1:

4.

32. The pharmaceutical formulation of any one of claims 1 to 31, wherein the formulation has a total ionic strength of 70 mM to 120 mM.

33. The pharmaceutical formulation of claim 32, wherein the total ionic strength is 80 mM ± 5 mM or 110 mM ± 10 mM.

34. The pharmaceutical formulation of any one of claims 1 to 33, having a vg / mL of 1 x 10E10 to 1 x 10E15 vg / mL.

35. The pharmaceutical formulation of claim 34, having 1 x 10E12 vg / mL to 1 x 10E14 vg / mL.

36. The pharmaceutical formulation of claim 35, having about 1 x 10E13 vg / mL.

37. A pharmaceutical formulation comprising (i) recombinant adeno-associated virus (rAAV) particles at a concentration of 1×10E10 vg / mL to 1×10E15 vg / mL, (ii) phosphate buffer at a concentration of 10 mM±1 mM, (iii) sodium chloride at a concentration of 30 mM±3 mM, (iv) L-arginine hydrochloride at a concentration of 80 mM±8 mM, (v) sucrose at a concentration of 5% w / v±0.5% w / v, (vi) mannitol at a concentration of 3.3% w / v±0.3% w / v, and (vii) poloxamer 188 at a concentration of 0.005% w / v±0.001% w / v, wherein the formulation has a pH of 7.3±0.

2.

38. A pharmaceutical formulation comprising (i) recombinant adeno-associated virus (rAAV) particles at a concentration of 1×10E10 vg / mL to 1×10E15 vg / mL, (ii) Tris buffer at a concentration of 10 mM±1 mM, (iii) sodium chloride at a concentration of 30 mM±3 mM, (iv) L-arginine hydrochloride at a concentration of 80 mM±8 mM, (v) sucrose at a concentration of 5% w / v±0.5% w / v, (vi) mannitol at a concentration of 3.3% w / v±0.3% w / v, and (vii) poloxamer 188 at a concentration of 0.01% w / v±0.002% w / v, wherein the formulation has a pH of 7.3±0.

2.

39. The pharmaceutical formulation of claim 37 or claim 38, wherein the concentration of the rAAV particles is 1 x 10E12 vg / mL to 1 x 10E14 vg / mL.

40. The pharmaceutical formulation of claim 37 or claim 38, wherein the concentration of the rAAV particles is about 1 x 10E13 vg / mL.

41. The pharmaceutical formulation of any one of claims 1 to 40, wherein the rAAV particles are of serotype AAV1, AAV2, AAV3, AAV4, AAV5, AAV6, AAV7, AAV8, AAV9, AAV-DJ, AAV-DJ / 8, AAV-Rh10, AAV-retro, AAV-PHP.B, AAV8-PHP.eB, or AAV-PHP.S.

42. The pharmaceutical formulation of claim 41, wherein the rAAV particles are of serotype AAV1, AAV2, AAV3, AAV4, AAV5, AAV6, AAV7, AAV8, AAV9, or AAV10.

43. The pharmaceutical formulation of claim 42, wherein the rAAV particles are of serotype AAV1.

44. The pharmaceutical formulation of claim 42, wherein the rAAV particles are of serotype AAV5.

45. The pharmaceutical formulation of claim 42, wherein the rAAV particles are of serotype AAV8.

46. ​​The pharmaceutical formulation of claim 42, wherein the rAAV particles are of serotype AAV9.

47. The pharmaceutical formulation of any one of claims 1 to 46, wherein the formulation has an average particle size of about 20 nm to about 40 nm as determined by dynamic light scattering.

48. The pharmaceutical formulation of any one of claims 1 to 47, wherein the formulation contains a population of rAAV particles comprising at least 95% complete capsids as determined by anion exchange chromatography.

49. A stable lyophilized pharmaceutical composition formed by lyophilizing the pharmaceutical formulation of any one of claims 1 to 48.

50. The lyophilized pharmaceutical composition of claim 49, having a moisture content of 1.5% or less.

51. The lyophilized pharmaceutical composition of claim 50, having a moisture content of 1.0% or less.

52. The lyophilized pharmaceutical composition of claim 51, having a moisture content of 0.5% to 0.8%, or 0.5%, 0.55%, 0.6%, 0.65%, 0.7%, 0.75% or 0.8%.

53. The lyophilized pharmaceutical composition of any one of claims 49 to 52, which can be reconstituted in 30 seconds or less.

54. The lyophilized pharmaceutical composition of claim 53, which can be reconstituted in 20 seconds or less.

55. The lyophilized pharmaceutical composition of claim 54, which can be reconstituted in 15 seconds or less.

56. A reconstituted drug product formed by reconstituting the lyophilized pharmaceutical composition of any one of claims 49 to 55.

57. The reconstituted drug product of claim 56 having an average particle size of about 20 nm to about 40 nm as determined by dynamic light scattering.

58. The reconstituted drug product of claim 56 or claim 57, comprising a population of rAAV particles comprising at least 95% complete capsids as determined by anion exchange chromatography.

59. A reconstituted drug product as described in any one of claims 56 to 58, comprising a population of rAAV particles comprising a certain percentage of complete capsids as determined by anion exchange chromatography, wherein the percentage of complete capsids in the reconstituted drug product is within 2% of the percentage of complete capsids in the drug formulation prior to lyophilization.

60. The reconstituted drug product of claim 59, wherein the percentage of complete capsids in the reconstituted drug product is within 1% of the percentage of complete capsids in the drug formulation prior to lyophilization.

61. The reconstituted drug product of claim 60, wherein the percentage of complete capsids in the reconstituted drug product is within 0.5% of the percentage of complete capsids in the drug formulation prior to lyophilization.

62. The reconstituted drug product of any one of claims 56 to 61, having a vector genome titer as determined by droplet digital polymerase chain reaction, wherein the vector genome titer in the reconstituted drug product is within 10% of the vector genome titer present in the drug formulation prior to lyophilization.

63. The reconstituted drug product of claim 62, wherein the vector genome titer in the reconstituted drug product is within 7% of the vector genome titer present in the drug formulation prior to lyophilization.

64. The reconstituted drug product of any one of claims 57 to 63, formed by reconstituting the lyophilized pharmaceutical composition after storage at a temperature of 2°C-8°C for 1 month.

65. The reconstituted drug product of any one of claims 57 to 63, formed by reconstituting the lyophilized pharmaceutical composition after storage at a temperature of 2°C-8°C for 3 months.

66. The reconstituted drug product of any one of claims 57 to 63, formed by reconstituting the lyophilized pharmaceutical composition after storage at a temperature of 2°C-8°C for 6 months.

67. A container comprising a pharmaceutical formulation as claimed in any one of claims 1 to 48.

68. A container comprising the lyophilized pharmaceutical composition of any one of claims 49 to 55.

69. A container containing a reconstituted drug product as claimed in any one of claims 56 to 66.

70. The container of any one of claims 67 to 69 which is a glass vial.

71. A kit comprising the container of any one of claims 67 to 70, and instructions for use.

72. A method for producing a stable lyophilized pharmaceutical composition according to any one of claims 49 to 55, the method comprising subjecting the pharmaceutical formulation according to any one of claims 1 to 48 to a lyophilization process.

73. The method of claim 72, wherein the lyophilization process comprises (i) freezing, (ii) annealing, (iii) primary drying, and (iv) secondary drying.

74. The method of claim 73, wherein the freezing is performed at a temperature of -45°C ± 5°C for a period of 60 minutes ± 10 minutes.

75. The method of claim 73 or claim 74, wherein the freezing is performed before and after the annealing.

76. The method of any one of claims 73 to 75, wherein the annealing is performed at a temperature of -20°C ± 5°C for a period of 6 hours ± 30 minutes.

77. The method of any one of claims 73 to 76, wherein the primary drying is carried out at a temperature of -26°C ± 5°C for a period of 50 hours ± 10 hours.

78. The method of any one of claims 73 to 77, wherein the secondary drying is carried out at a temperature of 35°C ± 5°C for a period of 5 to 20 hours or for a period of 15 hours ± 5 hours.